,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,13,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
6,15,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
7,19,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
8,21,1,1,,142727,4212,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
9,23,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
10,25,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
11,29,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
12,31,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
13,33,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
14,35,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
15,37,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
16,39,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
17,41,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
18,43,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
19,45,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
20,47,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
21,49,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
22,53,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
23,55,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
24,59,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
25,65,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
26,67,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
27,71,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
28,73,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
29,77,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
30,79,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
31,81,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
32,83,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
33,85,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
34,87,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
35,89,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
36,91,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
37,93,1,1,,142727,4212,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
38,95,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
39,97,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
40,99,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
41,101,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
42,103,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
43,105,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
44,107,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
45,109,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
46,113,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
47,115,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
48,119,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
49,121,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
50,123,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
51,125,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
52,129,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Confirmatory,,
53,131,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
54,133,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
55,137,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
56,139,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
57,141,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
58,143,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
59,145,1,1,,142727,4212,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
60,155,1,1,,142727,4212,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
61,157,1,1,,142727,4212,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
62,161,1,1,,142727,4212,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
63,165,1,1,,142727,4212,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
64,167,1,1,,142727,4212,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
65,175,1,1,,142727,4212,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
66,179,1,1,,142727,4212,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
67,188,1,1,,142727,4212,Unspecified,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Nontumored Animals (Toxicity Test) in CD2F1 (CDF1) mice,Other,,
68,192,1,1,,142727,4212,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
69,194,1,1,,142727,4212,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
70,196,1,1,,142727,4212,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intracerebral) in B6D2F1 (BDF1) mice,Other,,
71,200,1,1,,142727,4212,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6C3F1 mice,Other,,
72,206,1,1,,142727,4212,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
73,210,1,1,,142727,4212,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon 26 Adenocarcinoma (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
74,212,1,1,,142727,4212,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
75,220,1,1,,142727,4212,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,Other,,
76,222,1,1,,142727,4212,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Ependymoblastoma (intracerebral) in C57BL/6 mice,Other,,
77,256,1,1,,142727,4212,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
78,258,1,1,,142727,4212,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (subcutaneous) in CD2F1 (CDF1) mice,Other,,
79,264,1,1,,142727,4212,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
80,270,1,1,,142727,4212,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
81,274,1,1,,142727,4212,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intravenous) in B6D2F1 (BDF1) mice,Other,,
82,280,1,1,,142727,4212,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Amelanotic Melanoma (LOX) (intraperitoneal) in NU/NU BALB/C (nude) mice,Other,,
83,296,1,1,,142727,4212,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
84,328,1,1,,142727,4212,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
85,330,1,1,,142727,4212,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
86,357,2,1,,11111482,4212,Inconclusive,,,,,AP1 Signaling Pathway,Confirmatory,,
87,357,2,1,,11111483,4212,Inconclusive,,,,,AP1 Signaling Pathway,Confirmatory,,
88,410,1,5,,11111482,4212,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
89,410,1,5,,11111483,4212,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
90,411,2,1,,11111482,4212,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
91,411,2,1,,11111483,4212,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
92,444,1,1,,11111482,4212,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
93,444,1,1,,11111483,4212,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
94,445,3,1,,11111482,4212,Inconclusive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
95,445,3,1,,11111483,4212,Inconclusive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
96,446,1,1,,11111482,4212,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
97,446,1,1,,11111483,4212,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
98,447,1,1,,11111482,4212,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
99,447,1,1,,11111483,4212,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
100,448,1,2,,11111482,4212,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
101,448,1,2,,11111483,4212,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
102,450,1,2,,11111482,4212,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
103,450,1,2,,11111483,4212,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
104,451,1,2,,11111482,4212,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
105,451,1,2,,11111483,4212,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
106,526,1,1,,11111482,4212,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
107,526,1,1,,11111483,4212,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
108,530,1,1,,11111482,4212,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
109,530,1,1,,11111483,4212,Inconclusive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
110,584,1,3,,11111482,4212,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
111,584,1,3,,11111483,4212,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
112,585,1,4,,11111482,4212,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
113,585,1,4,,11111483,4212,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
114,587,1,5,,11111482,4212,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
115,587,1,5,,11111483,4212,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
116,588,1,4,,11111482,4212,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
117,588,1,4,,11111483,4212,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
118,589,1,3,,11111482,4212,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
119,589,1,3,,11111483,4212,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
120,590,1,3,,11111482,4212,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
121,590,1,3,,11111483,4212,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
122,591,1,4,,11111482,4212,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
123,591,1,4,,11111483,4212,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
124,592,1,6,,11111482,4212,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
125,592,1,6,,11111483,4212,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
126,593,1,4,,11111482,4212,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
127,593,1,4,,11111483,4212,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
128,594,1,4,,11111482,4212,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
129,594,1,4,,11111483,4212,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
130,595,1,3,,11111482,4212,Active,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
131,595,1,3,,11111483,4212,Inconclusive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
132,596,1,2,,11111482,4212,Active,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
133,596,1,2,,11111483,4212,Active,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
134,597,1,3,,11111482,4212,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
135,597,1,3,,11111483,4212,Inconclusive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
136,603,1,2,,11111482,4212,Active,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
137,603,1,2,,11111483,4212,Active,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
138,605,1,2,,11111482,4212,Active,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
139,605,1,2,,11111483,4212,Inconclusive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
140,607,1,3,,11111482,4212,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
141,607,1,3,,11111483,4212,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
142,662,1,1,,11111482,4212,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
143,662,1,1,,11111483,4212,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
144,875,1,2,,11111482,4212,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
145,875,1,2,,11111483,4212,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
146,879,1,2,,11111482,4212,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
147,879,1,2,,11111482,4212,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
148,880,2,1,,11111483,4212,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
149,880,2,1,,11111483,4212,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
150,881,2,2,,11111482,4212,Inactive,317373425.0,247.0,3.1623,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
151,881,2,2,,11111483,4212,Inactive,317373425.0,247.0,12.5893,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
152,883,1,3,,11111482,4212,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
153,883,1,3,,11111483,4212,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
154,884,1,2,,11111482,4212,Active,13435386.0,1576.0,25.1189,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
155,884,1,2,,11111483,4212,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
156,885,1,2,,11111482,4212,Inactive,13435386.0,1576.0,25.1189,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
157,885,1,2,,11111483,4212,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
158,886,1,2,,11111482,4212,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
159,886,1,2,,11111482,4212,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
160,886,1,2,,11111483,4212,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
161,886,1,2,,11111483,4212,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
162,887,1,2,,11111482,4212,Inactive,1832253.0,246.0,3.1623,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
163,887,1,2,,11111483,4212,Inactive,1832253.0,246.0,12.5893,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
164,889,1,3,,11111482,4212,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
165,889,1,3,,11111483,4212,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
166,891,1,2,,11111482,4212,Inconclusive,40805836.0,1565.0,39.8107,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
167,891,1,2,,11111483,4212,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
168,892,1,2,,11111482,4212,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
169,892,1,2,,11111483,4212,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
170,893,1,2,,11111482,4212,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
171,893,1,2,,11111482,4212,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
172,893,1,2,,11111483,4212,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
173,893,1,2,,11111483,4212,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
174,894,2,1,,11111483,4212,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
175,895,1,2,,11111482,4212,Active,21620132.0,4790.0,1.9953,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
176,899,1,2,,11111482,4212,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
177,899,1,2,,11111483,4212,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
178,900,1,3,,11111482,4212,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
179,900,1,3,,11111483,4212,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
180,901,1,2,,11111482,4212,Inconclusive,44888968.0,83523.0,10.0,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
181,901,1,2,,11111483,4212,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
182,902,1,2,,11111482,4212,Active,120407068.0,7157.0,15.8489,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
183,902,1,2,,11111483,4212,Inconclusive,120407068.0,7157.0,1.9953,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
184,912,1,2,,11111482,4212,Inconclusive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
185,912,1,2,,11111483,4212,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
186,914,1,3,,11111482,4212,Inconclusive,32879895.0,3091.0,12.5893,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
187,914,1,3,,11111483,4212,Inconclusive,32879895.0,3091.0,7.9433,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
188,915,1,3,,11111482,4212,Inconclusive,32879895.0,3091.0,12.5893,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
189,915,1,3,,11111483,4212,Inconclusive,32879895.0,3091.0,7.9433,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
190,917,1,3,,11111482,4212,Inconclusive,120660324.0,7066.0,0.0251,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
191,918,1,3,,11111482,4212,Active,120660324.0,7066.0,0.0251,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
192,923,1,2,,11111482,4212,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
193,923,1,2,,11111483,4212,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
194,924,1,2,,11111482,4212,Inconclusive,120407068.0,7157.0,7.9433,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
195,924,1,2,,11111483,4212,Inconclusive,120407068.0,7157.0,5.0119,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
196,925,1,2,,11111482,4212,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
197,925,1,2,,11111483,4212,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
198,926,1,2,,11111482,4212,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
199,926,1,2,,11111483,4212,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
200,927,1,3,,11111482,4212,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
201,927,1,3,,11111483,4212,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
202,928,1,2,,11111482,4212,Inconclusive,21620132.0,4790.0,1.9953,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
203,938,1,2,,11111482,4212,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
204,938,1,2,,11111483,4212,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
205,943,1,2,,11111482,4212,Inconclusive,18249941.0,25229.0,17.7828,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
206,944,1,2,,11111482,4212,Active,18249941.0,25229.0,5.0119,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
207,945,1,4,,11111482,4212,Inconclusive,290753097.0,,15.8489,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
208,954,1,2,,11111482,4212,Inactive,33286420.0,5315.0,19.9526,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
209,957,1,2,,11111482,4212,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
210,958,1,2,,11111482,4212,Inconclusive,33286420.0,5315.0,19.9526,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
211,959,1,4,,11111482,4212,Inactive,290753097.0,,15.8489,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
212,992,1,3,,11111482,4212,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
213,995,1,2,,11111482,4212,Active,66932916.0,5594.0,3.9811,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
214,995,1,2,,11111483,4212,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
215,997,1,2,,11111482,4212,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
216,998,1,2,,11111482,4212,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
217,1030,2,1,,11111483,4212,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
218,1332,1,1,,49698959,4212,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
219,1379,1,2,,11111483,4212,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
220,1452,1,1,,11111482,4212,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
221,1452,1,1,,11111483,4212,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
222,1454,1,1,,11111483,4212,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
223,1457,1,1,,11111483,4212,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
224,1458,1,1,,11111483,4212,Inactive,10937869.0,6607.0,0.7943,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
225,1467,1,3,,11111483,4212,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
226,1469,1,1,,11111483,4212,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
227,1471,2,1,,11111482,4212,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
228,1471,2,1,,11111483,4212,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
229,1476,2,1,,11111483,4212,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
230,1478,2,1,,11111483,4212,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
231,1479,1,2,,11111483,4212,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
232,1487,1,1,,11111483,4212,Inconclusive,27436948.0,4000.0,0.0708,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
233,1490,2,1,,11111483,4212,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
234,1519,1,3,,11111483,4212,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
235,1688,1,1,,11111483,4212,Active,90903231.0,3064.0,10.0,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
236,1766,1,1,,11111483,4212,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
237,1766,1,1,,11111483,4212,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
238,1768,1,1,,11111483,4212,Inconclusive,18860839.0,4221.0,14.1254,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
239,1768,1,1,,11111483,4212,Inconclusive,56550039.0,4297.0,14.1254,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
240,1811,3,2,,46394146,4212,Active,112490636.0,,,,Experimentally measured binding affinity data derived from PDB,Other,16674948.0,
241,1851,1,2,,11111483,4212,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
242,1851,1,2,1.0,11111483,4212,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
243,1851,1,2,2.0,11111483,4212,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
244,1851,1,2,3.0,11111483,4212,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
245,1851,1,2,4.0,11111483,4212,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
246,1851,1,2,5.0,11111483,4212,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
247,1865,1,1,,11111483,4212,Active,,,12.5893,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
248,1948,1,1,,11111483,4212,Inactive,,,1.2589,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
249,2101,1,1,,11111483,4212,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
250,2107,1,1,,11111483,4212,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
251,2112,1,1,,11111483,4212,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
252,2147,1,1,,11111483,4212,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
253,2240,1,1,,85788828,4212,Active,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
254,2241,1,1,,85788828,4212,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
255,2275,1,1,,85788828,4212,Active,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
256,2313,1,1,,85788828,4212,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
257,2317,2,2,,85856281,4212,Active,,,,,Late stage results from the probe development efforts to identify selective inhibitors of VIM-2 metallo-beta-lactamase: Prior art results,Screening,,
258,2317,2,2,1.0,85856281,4212,Active,7381449.0,14678525.0,1500.0,,Late stage results from the probe development efforts to identify selective inhibitors of VIM-2 metallo-beta-lactamase: Prior art results,Screening,,
259,2317,2,2,2.0,85856281,4212,Active,7381449.0,14678525.0,0.63,,Late stage results from the probe development efforts to identify selective inhibitors of VIM-2 metallo-beta-lactamase: Prior art results,Screening,,
260,2317,2,2,3.0,85856281,4212,Inactive,27368096.0,,56.0,,Late stage results from the probe development efforts to identify selective inhibitors of VIM-2 metallo-beta-lactamase: Prior art results,Screening,,
261,2317,2,2,4.0,85856281,4212,Unspecified,114881106.0,4290808.0,,,Late stage results from the probe development efforts to identify selective inhibitors of VIM-2 metallo-beta-lactamase: Prior art results,Screening,,
262,2322,1,1,,85788828,4212,Active,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
263,2330,1,1,,85788828,4212,Active,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
264,2451,1,2,,11111483,4212,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
265,2472,1,2,,11111483,4212,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
266,2528,1,2,,11111483,4212,Active,4557365.0,641.0,14.1254,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
267,2546,1,1,,11111483,4212,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
268,2549,1,1,,11111483,4212,Active,282403581.0,,12.5893,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
269,2551,1,1,,11111483,4212,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
270,2660,1,1,,90341083,4212,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
271,2662,2,1,,11111483,4212,Inconclusive,56550039.0,4297.0,12.5893,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
272,2666,1,1,,90341083,4212,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
273,2667,1,1,,90341083,4212,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
274,2668,1,1,,90341083,4212,Inconclusive,4826730.0,2475.0,0.1469,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
275,2708,1,1,,11111483,4212,Active,282403581.0,,28.1838,Potency,Confirmation qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
276,2711,1,1,,11111483,4212,Active,,,3.5481,Potency,Counterscreen for RECQ1 Inhibitors: ADP Fluorescence Polarization Displacement Assay,Confirmatory,,
277,2712,1,1,,11111483,4212,Active,,,3.5481,Potency,Counterscreen for BLMA Inhibitors: ADP Fluorescence Polarization Displacement Assay,Confirmatory,,
278,7465,6,3,,103167833,4212,Active,,,5.5,IC50,Compound was evaluated for cytotoxicity against A2780 cell lines.,Confirmatory,,
279,7501,4,4,,103167833,4212,Active,,,0.0251,IC50,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),Confirmatory,10479282.0,
280,8247,6,2,,103167833,4212,Active,,,0.03,IC50,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,Confirmatory,1447730.0,
281,8289,6,2,,103167833,4212,Active,,,0.3,IC50,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),Confirmatory,12036369.0,
282,8424,6,2,,103167833,4212,Active,,,0.18,IC50,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,Confirmatory,1447730.0,
283,8485,4,4,,103167833,4212,Active,,,0.0031,IC50,Tested against A549 lung carcinoma in the sulforhodamine B assay.,Confirmatory,8648600.0,
284,8690,4,4,,103167833,4212,Active,,,0.0031,IC50,Activity against A549 cancer cell line.,Confirmatory,8960558.0,
285,9065,6,2,,103167833,4212,Active,,,0.3,IC50,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,Confirmatory,12031316.0,
286,9611,6,2,,103167833,4212,Active,,,0.026000000000000002,IC50,Inhibitory activity against human tumor cell line A0375 melanoma.,Confirmatory,7853345.0,
287,10003,6,2,,103167833,4212,Active,,,0.00055,IC50,Concentration required to inhibit A2780-cell growth by 50%,Confirmatory,9703471.0,
288,10007,6,2,,103167833,4212,Active,,,0.00055,IC50,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,Confirmatory,9371240.0,
289,10019,4,4,,103167833,4212,Active,,,0.00611,IC50,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,Confirmatory,10479282.0,
290,15914,3,5,,103167833,4212,Unspecified,,,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,Other,,
291,15915,3,5,,103167833,4212,Unspecified,,,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,Other,,
292,25619,3,3,,103167833,4212,Unspecified,,,,,Estimated pKa value of the compound,Other,1573635.0,
293,26757,3,4,,103167833,4212,Inconclusive,,,,,DNA binding dissociation constant as KD; No data,Other,6708048.0,
294,27139,3,3,,103167833,4212,Unspecified,,,,,Apparent equilibrium constant for DNA binding (C-T),Other,12825949.0,
295,32544,4,4,,103167833,4212,Active,,,0.048,IC50,Inhibitory activity against AUC375 cell line,Confirmatory,8648600.0,
296,39730,3,6,,103167833,4212,Unspecified,,,,,Tested for activity against murine B-16 melanoma in mice and percent treated to the control values with the number of 60 day survivors,Other,3806589.0,
297,39734,4,1,,103167833,4212,Unspecified,,,,,Compound was tested against sc B16 melanoma at % tumor growth inhibition(TGI) in mice at 3.2 mg/kg dosage.,Other,8648600.0,
298,39742,3,5,,103167833,4212,Unspecified,,,,,Optimal dose per injection in mg/kg required to inhibit growth of murine B-16 melanoma in vivo,Other,3806589.0,
299,43704,6,2,,103167833,4212,Active,,,3.6,IC50,Cytotoxicity in human leukemic CCRF-CEM cells.,Confirmatory,14667232.0,
300,45639,3,6,,103167833,4212,Unspecified,,,,,Survivors of CDF1 mice on day 4 after 1st injection of compound 12 at mg/kg in six mice; 6/6,Other,2754697.0,
301,45643,3,6,,103167833,4212,Unspecified,,,,,Survivors of CDF1 mice on day 4 after 1st injection of compound at 0.75 mg/kg in six mice; 6/6,Other,2754697.0,
302,45645,3,6,,103167833,4212,Unspecified,,,,,Survivors of CDF1 mice on day 4 after 1st injection of compound at 1.5 mg/kg in six mice; 6/6,Other,2754697.0,
303,45652,3,6,,103167833,4212,Unspecified,,,,,Survivors of CDF1 mice on day 4 after 1st injection of compound at 3 mg/kg in six mice; 6/6,Other,2754697.0,
304,45657,3,6,,103167833,4212,Unspecified,,,,,Survivors of CDF1 mice on day 4 after 1st injection of compound at 6 mg/kg in six mice; 6/6,Other,2754697.0,
305,46133,7,1,,103167833,4212,Active,,,,,Inhibitory concentration against ethidium:calf thymus DNA (1.26:1) binding at pH 5,Other,9371240.0,
306,46135,7,1,,103167833,4212,Active,,,,,Inhibitory concentration against ethidium:Calf thymus DNA (1.26:1) binding at pH 7,Other,9371240.0,
307,46169,7,1,,103167833,4212,Active,,,,,Inhibitory concentration against ethidium:Calf thymus DNA(0.1:1) binding at pH 5,Other,9371240.0,
308,46325,3,4,,103167833,4212,Unspecified,,,,,Thermal denaturation of calf-thymus DNA was evaluated,Other,8340911.0,
309,47499,6,2,,103167833,4212,Active,,,0.00265,IC50,Cytotoxic potency required to inhibit CH1 cell growth by 50%,Confirmatory,9371240.0,
310,47668,6,2,,103167833,4212,Active,,,0.00265,IC50,Concentration required to inhibit CH1-cell growth by 50%,Confirmatory,9703471.0,
311,51931,6,2,,103167833,4212,Active,,,0.001,IC50,Tested for the cytotoxicity against the repair deficient xrs-6 chinese hamster ovary cell line,Confirmatory,7525959.0,
312,54104,4,1,,103167833,4212,Unspecified,,,,,Increase in Melting temperature (delta Tm) for Clostridium perfringens DNA on interaction against ligand (mole ratio of 10:1),Other,1573635.0,
313,54113,4,1,,103167833,4212,Unspecified,,,,,Increase in Melting temperature (delta Tm) for Micrococcus lysodeikticus DNA on interaction against ligand (mole ratio of 10:1),Other,1573635.0,
314,54438,6,2,,103167833,4212,Active,,,3.4,EC50,In vitro inhibition of calf thymus DNA/ethidium bromide complex formation.,Confirmatory,12036369.0,
315,54441,6,2,,103167833,4212,Active,,,0.4,EC50,In vitro calf thymus DNA binding affinity by ethidium bromide displacement,Confirmatory,12031316.0,
316,54626,3,3,,103167833,4212,Unspecified,,,,,Apparent equilibrium constant for binding to calf thymus DNA by competitive displacement fluorometric assay,Other,11563932.0,
317,54632,3,3,,103167833,4212,Unspecified,,,,,Binding affinity towards calf thymus DNA,Other,10411474.0,
318,54993,4,1,,103167833,4212,Unspecified,,,,,Compound was evaluated for the increase in melting temperature (delta Tm) for calf Thymus DNA on interaction with Ligand at DNAp to ligand ratio 10:1,Other,1573635.0,
319,54994,4,1,,103167833,4212,Unspecified,,,,,Compound was evaluated for the increase in melting temperature (delta Tm) for calf Thymus DNA on interaction with Ligand at DNAp to ligand ratio 20:1,Other,1573635.0,
320,54998,4,1,,103167833,4212,Unspecified,,,,,Increase in Melting temperature (delta Tm) for Calf thymus DNA on interaction against ligand (mole ratio of 10:1),Other,1573635.0,
321,55292,7,1,,103167833,4212,Active,,,,,CT-DNA binding required to produce a 50% drop in fluorescence of DNA-bound ethidium.,Other,11806721.0,
322,55499,7,1,,103167833,4212,Active,,,,,Concentration required to give 50% fluorescence quenching of bound ethidium for [ethidium]: [(poly dG-dC)]2 DNA in ratio of 0.1:1 at pH 5,Other,9371240.0,
323,55500,7,1,,103167833,4212,Active,,,,,Concentration required to give 50% fluorescence quenching of bound ethidium for [ethidium]: [poly(dA-dT)]2 DNA in ratio of 0.1:1 at pH 5,Other,9371240.0,
324,55805,4,4,,103167833,4212,Active,,,0.0056,IC50,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line DU145,Confirmatory,10479282.0,
325,57199,5,4,,103167833,4212,Active,,,,,In vitro inhibition of partially purified human ovarian carcinoma topoisomerase II of kDNA decatenation,Other,7473578.0,
326,67112,3,4,,103167833,4212,Unspecified,,,,,Percent colony reduction in cell growth in EBV-positive nasopharyngeal cell lines after administration of 0.1 ug/mL dose,Other,6685770.0,
327,67127,3,5,,103167833,4212,Unspecified,,,,,EBV-positive nasopharyngeal colony count obtained from the examination of uniform plate surface areas after a dose of 0.1 ug/mL,Other,6685770.0,
328,72412,6,2,,103167833,4212,Active,,,0.00065,IC50,Cytotoxic potency required to inhibit G-361 cell growth by 50%,Confirmatory,9371240.0,
329,80704,8,2,,103167833,4212,Inconclusive,,,,,Tested for the cytotoxicity to inhibit replication assay against the human colon tumor cell line HCT116; ND is Not Determined,Other,7525959.0,
330,81308,4,5,,103167833,4212,Active,,,0.00081,IC50,Compound was tested in vitro for cytotoxicity against HL60 human leukemia cell line (72 hr exposure to compound),Confirmatory,10479282.0,
331,81486,6,2,,103167833,4212,Active,,,3.35,IC50,"Relative cytotoxicity against Human promyelocytic Leukemia(HL-60) cells; Value is in range, activity expressed as IC50",Confirmatory,10377219.0,
332,81643,5,2,,103167833,4212,Active,,,,,"Relative cytotoxicity against Human promyelocytic Leukemia(HL-60) cells; Value is in range, activity expressed as IC90",Other,10377219.0,
333,83440,8,1,,103167833,4212,Active,,,0.09,ID50,Compound was tested for tumor cell growth inhibition against HL 60 cell line,Confirmatory,,
334,83602,4,4,,103167833,4212,Active,,,0.0196,IC50,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line HT-29,Confirmatory,10479282.0,
335,83618,6,2,,103167833,4212,Active,,,0.01,IC50,In vitro cytotoxicity was tested against human colon adenocarcinoma HT-29 cell line,Confirmatory,10411474.0,
336,83759,6,2,,103167833,4212,Active,,,0.017,IC50,Inhibitory activity against human tumor cell line HT-29.,Confirmatory,7853345.0,
337,83789,3,4,,103167833,4212,Unspecified,,,,,Percent inhibition at G1 phase of cell cycle at a dose of 100n g/mL after 72 hours of induction in HT-29 cell line,Other,10479282.0,
338,83790,3,4,,103167833,4212,Unspecified,,,,,Percent inhibition at G1 phase of cell cycle at a dose of 25 ng/mL after 72 hours of induction in HT-29 cell line,Other,10479282.0,
339,83791,3,4,,103167833,4212,Unspecified,,,,,Percent inhibition at G2/M phase of cell cycle at a dose of 100n g/mL after 72 hours of induction in HT-29 cell line,Other,10479282.0,
340,83792,3,4,,103167833,4212,Unspecified,,,,,Percent inhibition at G2/M phase of cell cycle at a dose of 25 ng/mL after 72 hours of induction in HT-29 cell line,Other,10479282.0,
341,83793,3,4,,103167833,4212,Unspecified,,,,,Percent inhibition at S phase of cell cycle at a dose of 100n g/mL after 72 hours of induction in HT-29 cell line,Other,10479282.0,
342,83794,3,4,,103167833,4212,Unspecified,,,,,Percent inhibition at S phase of cell cycle at a dose of 25 ng/mL after 72 hours of induction in HT-29 cell line,Other,10479282.0,
343,83926,3,5,,103167833,4212,Unspecified,,,,,Effect of compound as percent survival at dose of 100n g/mL on HT-29 cell line after 72 hours,Other,10479282.0,
344,83927,3,5,,103167833,4212,Unspecified,,,,,Effect of compound as percent survival at dose of 25 ng/mL on HT-29 cell line after 72 hours,Other,10479282.0,
345,84105,4,4,,103167833,4212,Active,,,2.025,IC50,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line HT-29/Mx,Confirmatory,10479282.0,
346,84106,3,4,,103167833,4212,Unspecified,,,,,Percent inhibition at G1 phase of cell cycle at a dose of 1000 ng/mL after 72 hours of induction in HT-29 cell line,Other,10479282.0,
347,84110,3,4,,103167833,4212,Unspecified,,,,,Percent inhibition at G1 phase of cell cycle at a dose of 250 ng/mL after 72 hours of induction in HT-29/Mx cell line,Other,10479282.0,
348,84111,4,4,,103167833,4212,Unspecified,,,,,Percent inhibition at G2/M phase of cell cycle at a dose of 100n g/mL after 72 hours of induction in HT-29/Mx cell line,Other,10479282.0,
349,84114,3,4,,103167833,4212,Unspecified,,,,,Percent inhibition at S phase of cell cycle at a dose of 1000 ng/mL after 72 hours of induction in HT-29/Mx cell line,Other,10479282.0,
350,84118,3,4,,103167833,4212,Unspecified,,,,,Percent inhibition at S phase of cell cycle at a dose of 250 ng/mL after 72 hours of induction in HT-29/Mx cell line,Other,10479282.0,
351,84119,3,5,,103167833,4212,Unspecified,,,,,Effect of compound as percent survival at dose of 1000 ng/mL on HT-29/Mx cell line after 72 hours,Other,10479282.0,
352,84123,3,5,,103167833,4212,Unspecified,,,,,Effect of compound as percent survival at dose of 250 ng/mL on HT-29/Mx cell line after 72 hours,Other,10479282.0,
353,84124,3,5,,103167833,4212,Unspecified,,,,,Effect of compound as percent survival at dose of 3000 ng/mL on HT-29/Mx cell line after 72 hours,Other,10479282.0,
354,84288,4,4,,103167833,4212,Active,,,0.01,IC50,In vitro cytotoxic potency against HT-29 (human colon adenocarcinoma) cell line.,Confirmatory,11806721.0,
355,84437,6,2,,103167833,4212,Active,,,0.01,IC50,Cytotoxic potency required to inhibit HT-29 cell growth by 50% after cell drug contact for 144 hrs,Confirmatory,9371240.0,
356,84475,6,2,,103167833,4212,Active,,,8.0,IC50,Inhibitory concentration of compound against proliferation of colon carcinoma HT-29 cell line,Confirmatory,12031316.0,
357,85581,6,2,,103167833,4212,Active,,,0.066,IC50,Inhibitory activity against human tumor cell line HT1080.,Confirmatory,7853345.0,
358,85749,6,2,,103167833,4212,Active,,,0.01,IC50,Concentration required to inhibit cell growth by 50% in vitro against Human colon adenocarcinoma cell line,Confirmatory,11563932.0,
359,85757,6,2,,103167833,4212,Active,,,8.0,IC50,In vitro cytotoxic activity against human colon HT-29 cell line ( standard deviation in parenthesis),Confirmatory,12036369.0,
360,87741,6,2,,103167833,4212,Unspecified,,,,,Effective concentration required to inhibit by 50% the growth of HeLa S3 cells,Other,3172129.0,
361,88706,8,1,,103167833,4212,Active,,,2.77,ID50,Compound was tested for tumor cell growth inhibition against HeLa cell line,Confirmatory,,
362,89435,8,1,,103167833,4212,Active,,,0.27,ID50,In vitro inhibitory activity against MCF-7 mammary cell line,Confirmatory,8340911.0,
363,90440,6,2,,103167833,4212,Active,,,0.01,IC50,In vitro cytotoxic activity against human colon adenocarcinoma (HT-29).,Confirmatory,12825949.0,
364,91425,9,5,,103167833,4212,Active,82312013.0,,3.8,IC50,"Inhibition of HIV-1 integrase, under 1 uM for the 3''-preprocessing",Confirmatory,10841789.0,
365,91426,9,5,,103167833,4212,Active,82312013.0,,8.0,IC50,"Tested for inhibition of HIV-1 integrase, under 1 uM for the strand transfer",Confirmatory,10841789.0,
366,95160,4,5,,103167833,4212,Active,,,0.0070599999999999994,IC50,Compound was tested in vitro for cytotoxicity against MDR cell line K562R (72 hr exposure to compound),Confirmatory,10479282.0,
367,95161,4,5,,103167833,4212,Active,,,0.1335,IC50,Compound was tested in vitro for cytotoxicity against MDR cell line K562R (RI) (72 hr exposure to compound),Confirmatory,10479282.0,
368,96628,8,1,,103167833,4212,Unspecified,,,1550000.0,ID50,Antitumor activity against L1210 lymphocytic cells in vitro,Confirmatory,6699870.0,
369,96751,3,4,,103167833,4212,Unspecified,,,,,Effect of dosing on LI210 leukemia in vivo measured as mean at 0.75 mg/kg,Other,3351863.0,
370,96755,3,4,,103167833,4212,Unspecified,,,,,"Effect of dosing on LI210 leukemia in vivo measured as mean at 0.4 mg/kg (cumulative dose 6.8 mg/Kg) with ip day 1,5&9 (once daily)",Other,3351863.0,
371,97056,3,4,,103167833,4212,Unspecified,,,,,"In vivo effect of dosing on LI210 leukemia measured as range at 0.4 mg/kg (cumulative dose 6.8 mg/Kg) with ip day 1,5&9 (once daily); value range 15 to 20",Other,3351863.0,
372,97252,3,4,,103167833,4212,Unspecified,,,,,Compound was tested against L1210 leukemia at % increase in life span (ILS) in mice at 1.6 mg/kg dosage.,Other,8648600.0,
373,97831,6,2,,103167833,4212,Unspecified,,,,,Effective concentration required to inhibit by 50% the growth of L1210 cells,Other,3172129.0,
374,98202,4,5,,103167833,4212,Active,,,0.039,IC50,Antitumor activity against murine L1210 resistant cell line by using MTT assay,Confirmatory,7699715.0,
375,98203,4,4,,103167833,4212,Active,,,0.005,IC50,Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay,Confirmatory,7699715.0,
376,98310,6,2,,103167833,4212,Active,,,0.1,IC50,Dose level for 50% inhibition of L1210 cell growth was measured after 24 h.,Confirmatory,3351863.0,
377,98312,6,2,,103167833,4212,Active,,,0.1,IC50,Dose level for 50% inhibition of L1210 cell growth was measured after 48 hr.,Confirmatory,3351863.0,
378,98355,6,2,,103167833,4212,Active,,,0.04,IC50,Inhibitory concentration of compound against proliferation of murine leukemia L1210 cell line,Confirmatory,12031316.0,
379,98384,4,4,,103167833,4212,Active,,,0.0097,IC50,Antitumor activity against sensitive L1210 murine leukemia cell lines.,Confirmatory,8960558.0,
380,98386,4,4,,103167833,4212,Active,,,0.039,IC50,Antitumor activity against murine leukemia L1210 cell line.,Confirmatory,8960558.0,
381,98403,6,2,,103167833,4212,Active,,,0.0016,IC50,Tested in vitro against murine L1210 leukemia.,Confirmatory,3806589.0,
382,98537,4,5,,103167833,4212,Active,,,0.0114,IC50,Compound was tested in vitro for cytotoxicity against L1210 murine cell line (48 hr exposure to compound),Confirmatory,10479282.0,
383,98563,6,2,,103167833,4212,Active,,,4e-05,IC50,Cytotoxic potency required to inhibit L1210 cell growth by 50% after cell drug contact for 48 hrs,Confirmatory,9371240.0,
384,98865,3,4,,103167833,4212,Unspecified,,,,,"Percentage increase in lifespan of mice in L1210 leukemia cells (in vivo) at 0.4 mg/kg (cumulative dose 6.8 mg/Kg) with ip day 1,5&9 (once daily)",Other,3351863.0,
385,98871,3,4,,103167833,4212,Unspecified,,,,,Percentage increase in lifespan of mice was measured (in vivo) at 0.75 mg/kg dose,Other,3351863.0,
386,98910,4,4,,103167833,4212,Active,,,0.039,IC50,Inhibitory activity against resistant murine leukemia L1210 cell lines.,Confirmatory,8648600.0,
387,98911,4,4,,103167833,4212,Active,,,0.0097,IC50,Inhibitory activity against sensitive L1210 cell lines,Confirmatory,8648600.0,
388,99088,6,2,,103167833,4212,Unspecified,,,,,Tested in vitro for inhibitory activity against L1210 murine leukemia,Other,8145234.0,
389,99358,4,4,,103167833,4212,Active,,,0.039,IC50,"Tested for inhibitory activity against murine cell line L12110, a strain resistant to doxorubicin using MTT assay.",Confirmatory,10956214.0,
390,99359,4,4,,103167833,4212,Active,,,0.01,IC50,"Tested for inhibitory activity against murine cell line L12110, a strain sensitive to doxorubicin using MTT assay.",Confirmatory,10956214.0,
391,100154,3,4,,103167833,4212,Unspecified,,,,,Number of tumor free survivors of mice was measured (in vivo) at a 0.75 mg/kg dose (cumulative dose 225 mg/kg),Other,3351863.0,
392,100158,3,4,,103167833,4212,Unspecified,,,,,"Number of tumor free survivors of mice was measured in L1210 leukemia cells (in vivo) at 0.4 mg/kg (cumulative dose 6.8 mg/Kg) with ip day 1,5&9 (once daily)",Other,3351863.0,
393,100159,3,4,,103167833,4212,Unspecified,,,,,Number of tumor free survivors of mice was measured in L1210 leukemia cells (in vivo) at 3 mg/kg (cumulative dose 9 mg/kg) with ip day 1-9 (twice daily); value give as 7/10,Other,3351863.0,
394,100166,3,4,,103167833,4212,Unspecified,,,,,Number of mice dead with 0.75 mg/kg dose (in vivo),Other,3351863.0,
395,101065,6,2,,103167833,4212,Active,,,0.002,IC50,In vitro extracellular concentration required to reduce cell population to 50% against L1210 leukemia cells,Confirmatory,1573635.0,
396,101603,6,2,,103167833,4212,Active,,,0.02,IC50,Inhibitory activity against human tumor cell line MCF-7 breast adenocarcinoma.,Confirmatory,7853345.0,
397,101787,6,2,,103167833,4212,Active,,,1.0,IC50,In vitro cytotoxic activity against human breast MDA-MB-231 cell line ( standard deviation in parenthesis),Confirmatory,12036369.0,
398,102033,6,2,,103167833,4212,Unspecified,,,,,In vitro cytotoxic activity against human colon adenocarcinoma resistant to doxorubicin (LoVo Dx) cells.,Other,10698460.0,
399,102168,4,4,,103167833,4212,Active,,,0.0171,IC50,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line LoVo,Confirmatory,10479282.0,
400,102172,6,2,,103167833,4212,Active,,,0.046,IC50,In vitro cytotoxicity was tested against human colon adenocarcinoma LoVo cell line,Confirmatory,10411474.0,
401,102184,6,2,,103167833,4212,Active,,,0.0097,IC50,Inhibitory activity against human colon adenocarcinoma cell line LoVo.,Confirmatory,7853345.0,
402,102188,6,2,,103167833,4212,Unspecified,,,,,Tested in vitro for cytotoxic activity against Human colon Adenocarcinoma sensitive cell line (LoVo),Other,8145234.0,
403,102201,6,2,,103167833,4212,Unspecified,,,,,In vitro cytotoxic activity against human colon adenocarcinoma (LoVo) cells,Other,10698460.0,
404,102203,6,2,,103167833,4212,Unspecified,,,,,In vitro cytotoxicity on human colon adenocarcinoma (LoVo ) tumor cell line.,Other,9876113.0,
405,102325,4,4,,103167833,4212,Active,,,0.461,IC50,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line LoVo/Dx(RI),Confirmatory,10479282.0,
406,102330,6,2,,103167833,4212,Active,,,0.53,IC50,Inhibitory activity against human colon adenocarcinoma cell line LoVo/Dx.,Confirmatory,7853345.0,
407,102331,6,2,,103167833,4212,Unspecified,,,,,Tested in vitro for cytotoxic activity against Doxorubicin resistant Human colon Adenocarcinoma sensitive cell line,Other,8145234.0,
408,102333,6,2,,103167833,4212,Unspecified,,,,,In vitro cytotoxicity on human colon adenocarcinoma resistant to doxorubicin (LoVo/Dx ) tumor cell line.,Other,9876113.0,
409,102334,6,2,,103167833,4212,Active,,,1.29,IC50,In vitro cytotoxicity was tested against human colon adenocarcinoma LoVo/Dx resistant cell line,Confirmatory,10411474.0,
410,102335,3,5,,103167833,4212,Unspecified,,,,,Resistance index is IC50 ratio of LoVo/Dx to LoVo,Other,10411474.0,
411,102597,6,2,,103167833,4212,Active,,,0.005,IC50,In vitro inhibition of tumor cell growth in the human mammary tumor MCF-7 system,Confirmatory,1447730.0,
412,103088,6,2,,103167833,4212,Active,,,4.0,IC50,In vitro inhibition of tumor cell growth in the human mammary carcinoma MCF-7/ADR system.,Confirmatory,1447730.0,
413,103419,4,4,,103167833,4212,Active,,,0.07200000000000001,IC50,"Tested for inhibitory activity against human tumor cell line D40, a strain resistant to doxorubicin of breast carcinoma using sulforhodamine B assay.",Confirmatory,10956214.0,
414,103420,4,4,,103167833,4212,Active,,,0.040999999999999995,IC50,"Tested for inhibitory activity against human tumor cell line MCF7, a strain resistant to mitoxantrone of breast carcinoma using sulforhodamine B assay.",Confirmatory,10956214.0,
415,103421,4,4,,103167833,4212,Active,,,0.009000000000000001,IC50,"Tested for inhibitory activity against human tumor cell line MCF7, a strain sensitive to doxorubicin of breast carcinoma using sulforhodamine B assay.",Confirmatory,10956214.0,
416,106265,3,5,,103167833,4212,Unspecified,,,,,In vivo antitumor activity was measured on MX-1 human mammary carcinoma cells. TWI%=tumor weight inhibition. Optimal dose at 3 mg/kg/day,Other,9876113.0,
417,106292,4,4,,103167833,4212,Active,,,0.07200000000000001,IC50,Tested against MXF7 breast carcinoma (doxorubicin resistant) cell line in the sulforhodamine B assay.,Confirmatory,8648600.0,
418,106293,4,4,,103167833,4212,Active,,,0.040999999999999995,IC50,Tested against MXF7 breast carcinoma (mitoxantrone resistant)cell line in the sulforhodamine B assay.,Confirmatory,8648600.0,
419,106294,4,4,,103167833,4212,Active,,,0.0087,IC50,Tested against MXF7 breast carcinoma (sensitive) cell line in the sulforhodamine B assay.,Confirmatory,8648600.0,
420,106296,4,4,,103167833,4212,Active,,,0.040999999999999995,IC50,Antitumor activity against human mammary carcinoma mitoxantrone-resistant MXF7 breast cell line.,Confirmatory,8960558.0,
421,106430,4,4,,103167833,4212,Active,,,0.07200000000000001,IC50,Antitumor activity against human mammary carcinoma doxorubicin-resistant MXF7 breast cell line.,Confirmatory,8960558.0,
422,106431,4,4,,103167833,4212,Active,,,0.0087,IC50,Antitumor activity against human mammary carcinoma sensitive MXF7 breast cell line.,Confirmatory,8960558.0,
423,107214,4,4,,103167833,4212,Active,,,0.048,IC50,Tested for inhibitory activity against human tumor cell line UA375 of melanoma using sulforhodamine B assay.,Confirmatory,10956214.0,
424,107941,6,1,,103167833,4212,Unspecified,,,,,Compound was evaluated in vivo for the antitumor activity at a dose of 1.25 mg/kg & 3.75 mg/kg against mammary adenocarcinoma 16C to assess tumor growth delay (T-C).,Other,6699870.0,
425,107942,6,1,,103167833,4212,Unspecified,,,,,Compound was evaluated in vivo for the antitumor activity at a dose of 2.5 mg/kg & 7.5 mg/kg against mammary adenocarcinoma 16C to assess tumor growth delay (T-C),Other,6699870.0,
426,107945,3,4,,103167833,4212,Unspecified,,,,,In vivo antitumor activity at a single dose of 12.5 mg/kg & 37.5 mg/kg total against mammary adenocarcinoma 16C,Other,6699870.0,
427,107946,3,4,,103167833,4212,Unspecified,,,,,In vivo antitumor activity at a single dose of 6.5 mg/kg & 18.8 mg/kg total against mammary adenocarcinoma 16C,Other,6699870.0,
428,110796,3,3,,103167833,4212,Unspecified,,,,,Number of mice(with Colon 38 tumors) cured after treatment of 3.9 mg/kg/day dose given as 3 times in a day for 4 days out of 5 mice,Other,12620081.0,
429,114263,6,1,,103167833,4212,Unspecified,,,,,In vivo antitumor activity against subcutaneous Colon 38 tumors in mice determined as delay in growth after 3.9 mg/kg/day dose given as 3 times in a day for 4 days,Other,12620081.0,
430,115197,3,4,,103167833,4212,Unspecified,,,,,"The percent increase in life span of compound was measured against P388 Leukemia cells in mice at at a dose of 1.6 mg/kg on days 1,5 and 9",Other,7699715.0,
431,116824,3,4,,103167833,4212,Unspecified,,,,,Percent increase in life span when given at a dose in P388 leukemia cells of mice,Other,8960558.0,
432,121351,3,3,,103167833,4212,Unspecified,,,,,"Therapeutic effect against P388 leukemia in mice on days 1, 5 and 9 after administration of 1.6 mg/kg dose expressed as median survival time of treated and control mice (in vivo)",Other,8340911.0,
433,127618,3,6,,103167833,4212,Unspecified,,,,,In vivo for the optimal dose for activity against P388 leukemia per injection,Other,3397990.0,
434,127620,3,4,,103167833,4212,Unspecified,,,,,The compound was evaluated in vivo for the optimal dose for activity against murine B-16 melanoma,Other,3397990.0,
435,129072,3,3,,103167833,4212,Unspecified,,,,,"Antileukemic activity towards P388 Murine Leukemia at a dose of 0.1 mg/kg, expressed as body weight change",Other,10479282.0,
436,129073,3,3,,103167833,4212,Unspecified,,,,,"Antileukemic activity towards P388 Murine Leukemia at a dose of 0.2 mg/kg, expressed as body weight change",Other,10479282.0,
437,129074,3,3,,103167833,4212,Unspecified,,,,,"Antileukemic activity towards P388 Murine Leukemia at a dose of 0.4 mg/kg, expressed as body weight change",Other,10479282.0,
438,129075,3,3,,103167833,4212,Unspecified,,,,,"Antileukemic activity towards P388 Murine Leukemia at a dose of 0.8 mg/kg, expressed as body weight change",Other,10479282.0,
439,130603,8,1,,103167833,4212,Active,,,0.01,ID50,In vitro inhibitory activity against L1210 leukemia cell line,Confirmatory,8340911.0,
440,132862,6,2,,103167833,4212,Active,,,0.0016,IC50,In vitro for its inhibitory activity against murine L1210 leukemia,Confirmatory,3397990.0,
441,134227,8,1,,103167833,4212,Unspecified,,,,,The compound was tested for antitumor activity against P388 murine leukemia by measuring maximum tolerated dose,Other,8145234.0,
442,134572,5,1,,103167833,4212,Active,,,0.01,LD50,In vitro cytotoxicity against L1210 leukemia cell line,Confirmatory,8340911.0,
443,135058,3,3,,103167833,4212,Unspecified,,,,,"In vivo antileukemic activity towards P388 Murine Leukemia at a dose of 0.1 mg/kg, expressed as long time survivors tested in 12 animals",Other,10479282.0,
444,135059,3,3,,103167833,4212,Unspecified,,,,,"In vivo antileukemic activity towards P388 Murine Leukemia at a dose of 0.2 mg/kg, expressed as long time survivors tested in 6 animals",Other,10479282.0,
445,135060,3,3,,103167833,4212,Unspecified,,,,,"In vivo antileukemic activity towards P388 Murine Leukemia at a dose of 0.4 mg/kg, expressed as long time survivors tested in 12 animals",Other,10479282.0,
446,135061,3,3,,103167833,4212,Unspecified,,,,,"In vivo antileukemic activity towards P388 Murine Leukemia at a dose of 0.8 mg/kg, expressed as long time survivors tested in 6 animals",Other,10479282.0,
447,135278,3,7,,103167833,4212,Unspecified,,,,,Net log value for P388 leukemia cell kill in mice was determined,Other,3397990.0,
448,135709,4,4,,103167833,4212,Unspecified,,,,,Tested for antitumor activity against P388 murine leukemia,Other,8145234.0,
449,135719,3,3,,103167833,4212,Unspecified,,,,,The compound was tested for antitumor activity against P388 murine leukemia by measuring median survival time of treated mice/median survival time of control x 100,Other,8145234.0,
450,136069,3,4,,103167833,4212,Unspecified,,,,,Antileukemic activity towards P388 Murine Leukemia at a dose of 0.1 mg/kg,Other,10479282.0,
451,136070,3,4,,103167833,4212,Unspecified,,,,,Antileukemic activity towards P388 Murine Leukemia at a dose of 0.2 mg/kg,Other,10479282.0,
452,136071,3,4,,103167833,4212,Unspecified,,,,,Antileukemic activity towards P388 Murine Leukemia at a dose of 0.4 mg/kg,Other,10479282.0,
453,136072,3,4,,103167833,4212,Unspecified,,,,,Antileukemic activity towards P388 Murine Leukemia at a dose of 0.8 mg/kg,Other,10479282.0,
454,137724,3,5,,103167833,4212,Unspecified,,,,,Percentage ratio of treated animals to cured animals against P388 leukemia (day 30 surv),Other,3397990.0,
455,137725,3,4,,103167833,4212,Unspecified,,,,,Percentage ratio of treated animals to cured animals against murine B-16 melanoma (day 60 surv),Other,3397990.0,
456,140016,3,3,,103167833,4212,Unspecified,,,,,The compound was tested for antitumor activity against P388 murine leukemia at 2 (mg/kg/day) dose; 0/82 -no. of toxic deaths/no. of mice,Other,8145234.0,
457,140019,3,3,,103167833,4212,Unspecified,,,,,The compound was tested for antitumor activity against P388 murine leukemia at 3 (mg/kg/day) dose; 12/132 -no. of toxic deaths/no. of mice,Other,8145234.0,
458,140020,3,3,,103167833,4212,Unspecified,,,,,The compound was tested for antitumor activity against P388 murine leukemia at 4 (mg/kg/day) dose; 43/48 -no. of toxic deaths/no. of mice,Other,8145234.0,
459,145432,4,4,,103167833,4212,Active,,,0.0058,IC50,Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay,Confirmatory,7699715.0,
460,145436,4,4,,103167833,4212,Active,,,0.0058,IC50,Antitumor activity against human ovarian OVCAR-3 cell lines.,Confirmatory,8960558.0,
461,145445,4,4,,103167833,4212,Active,,,0.0058,IC50,Inhibitory activity against OVCAR-3 cell line,Confirmatory,8648600.0,
462,150676,6,2,,103167833,4212,Active,,,27.56,IC50,"Relative cytotoxicity against Human bone marrow samples; Value is in range, activity expressed as IC50",Confirmatory,10377219.0,
463,150691,5,2,,103167833,4212,Active,,,,,"Relative cytotoxicity against Human bone marrow samples; Value is in range, activity expressed as IC90",Other,10377219.0,
464,152516,3,6,,103167833,4212,Unspecified,,,,,"Activity against P388 leukemia cells in mice, by intraperitoneal dosing and net log tumor cell kill was reported",Other,3806589.0,
465,152915,3,4,,103167833,4212,Unspecified,,,,,In vivo antitumor activity was measured on systemic P388 murine leukemia cells. Optimal dose at 3 mg/kg/day,Other,9876113.0,
466,153418,3,4,,103167833,4212,Unspecified,,,,,Compound was tested against P388 leukemia at % increase in life span (ILS) in mice at 1.6 mg/kg dosage.,Other,8648600.0,
467,153494,3,4,,103167833,4212,Unspecified,,,,,In vivo antineoplastic activity was determined in BDF1 mice implanted with P388 leukemia and activity is expressed as T/C at 0.06 mg/kg,Other,3625713.0,
468,153495,3,4,,103167833,4212,Unspecified,,,,,In vivo antineoplastic activity was determined in BDF1 mice implanted with P388 leukemia and activity is expressed as T/C at 0.12 mg/kg,Other,3625713.0,
469,153496,3,4,,103167833,4212,Unspecified,,,,,In vivo antineoplastic activity was determined in BDF1 mice implanted with P388 leukemia and activity is expressed as T/C at 0.25 mg/kg,Other,3625713.0,
470,153497,3,4,,103167833,4212,Unspecified,,,,,In vivo antineoplastic activity was determined in BDF1 mice implanted with P388 leukemia and activity is expressed as T/C at 0.5 mg/kg,Other,3625713.0,
471,153498,3,4,,103167833,4212,Unspecified,,,,,In vivo antineoplastic activity was determined in BDF1 mice implanted with P388 leukemia and activity is expressed as T/C at 1 mg/kg,Other,3625713.0,
472,153505,3,4,,103167833,4212,Unspecified,,,,,In vivo antineoplastic activity was determined in BDF1 mice implanted with P388 leukemia and activity is expressed as T/C at 2 mg/kg,Other,3625713.0,
473,153899,3,4,,103167833,4212,Unspecified,,,,,In vivo antitumor activity against P388 leukemia cells at a dose of 0.75 mg/kg as a single injection and 1.5 mg/kg as a total,Other,6699870.0,
474,153900,3,4,,103167833,4212,Unspecified,,,,,In vivo antitumor activity against P388 leukemia cells at a dose of 1.5 mg/kg as a single injection and 3 mg/kg as a total,Other,6699870.0,
475,154065,3,6,,103167833,4212,Unspecified,,,,,"Inhibition of P388 leukemia cells in mice, measured as percent treated to the control values with the number of 30 day survivors",Other,3806589.0,
476,154372,3,5,,103167833,4212,Unspecified,,,,,Optimal dose per injection in mg/kg required to inhibit growth of P388 leukemia cells in mice,Other,3806589.0,
477,154566,3,5,,103167833,4212,Unspecified,,,,,Percent ratio of the medium survival time for P388 murine leukemia in CDF1 mice at 0.75 mg/kg,Other,2754697.0,
478,154568,3,5,,103167833,4212,Unspecified,,,,,Percent ratio of the medium survival time for P388 murine leukemia in CDF1 mice at 1.5 mg/kg,Other,2754697.0,
479,154570,3,5,,103167833,4212,Unspecified,,,,,Percent ratio of the medium survival time for P388 murine leukemia in CDF1 mice at 12 mg/kg,Other,2754697.0,
480,154575,3,5,,103167833,4212,Unspecified,,,,,Percent ratio of the medium survival time for P388 murine leukemia in CDF1 mice at 3 mg/kg,Other,2754697.0,
481,154579,3,5,,103167833,4212,Unspecified,,,,,Percent ratio of the medium survival time for P388 murine leukemia in CDF1 mice at 6 mg/kg,Other,2754697.0,
482,156652,4,4,,103167833,4212,Active,,,0.0071,IC50,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line PC3,Confirmatory,10479282.0,
483,170463,3,3,,103167833,4212,Unspecified,,,,,Cardiotoxicity by a neonatal rat heart myocyte assay,Other,8648600.0,
484,171537,3,3,,103167833,4212,Unspecified,,,,,Cardiotoxicity measured by the ATP/protein ratio compared with untreated controls using neonatal rat heart myocyte assay.,Other,8960558.0,
485,196905,3,3,,103167833,4212,Active,,,,,Cardiotoxicity was measured by using Neonatal rat heart myocyte assay,Other,7699715.0,
486,200620,6,2,,103167833,4212,Active,,,0.02,IC50,Cytotoxicity against human small-cell lung cancer (SCLC),Confirmatory,8258835.0,
487,200624,6,2,,103167833,4212,Active,,,0.03,IC50,Cytotoxicity against human SCLC cells resistant to cisplatin (SCLC/CDDP),Confirmatory,8258835.0,
488,200757,6,4,,103167833,4212,Active,,,0.0053,IC50,Compound was evaluated for cytotoxicity against SCOV-3 cell lines.,Confirmatory,,
489,201222,3,4,,103167833,4212,Unspecified,,,,,Bacterial mutagenicity was measured against Salmonella Typhimurium TA1538 at dose range of 0-5 ug/plate,Other,9733500.0,
490,201223,3,4,,103167833,4212,Unspecified,,,,,Bacterial mutagenicity was measured against Salmonella Typhimurium TA97a at dose range of 0-400 ug/plate,Other,9733500.0,
491,201224,3,4,,103167833,4212,Unspecified,,,,,Bacterial mutagenicity was measured against Salmonella Typhimurium TA98 at dose range of 0-10 ug/plate,Other,9733500.0,
492,201633,6,2,,103167833,4212,Active,,,0.016,IC50,The IC50 value was measured on human breast cancer cell line SK-BR-3.,Confirmatory,7699696.0,
493,202628,5,2,,103167833,4212,Unspecified,,,,,Mean percentage reduction in tumor weight at 0.75 mg/kg (cumulative dose 525 mg/Kg) introduced (in vivo) ip; Significant,Other,3351863.0,
494,202642,3,5,,103167833,4212,Unspecified,,,,,Mean percentage reduction in tumor weight on S180 tumor cell at 0.75 mg/kg (cumulative dose 16 mg/Kg) introduced ip (in vivo),Other,3351863.0,
495,202783,3,5,,103167833,4212,Unspecified,,,,,Percentage of tumor free survivors of mice at 0.75 mg/kg (cumulative dose 525 mg/Kg) introduced (in vivo) ip; value given as 0/10,Other,3351863.0,
496,202844,6,2,,103167833,4212,Active,,,0.0053,IC50,Concentration required to inhibit SKOV-3-cell growth by 50%,Confirmatory,9703471.0,
497,202924,3,5,,103167833,4212,Unspecified,,,,,Number of mice dead with toxic dose was measured on S180 tumor cell at 0.75 mg/kg (cumulative dose 16 mg/kg) introduced (in vivo) ip,Other,3351863.0,
498,202961,6,2,,103167833,4212,Active,,,0.0053,IC50,Cytotoxic potency required to inhibit SKOV-3 cell growth 50%,Confirmatory,9371240.0,
499,211122,5,3,,103167833,4212,Active,,,,,Effect of dose dependent inhibition of TOPO II-catalyzed kDNA decatenation in vitro,Other,7525959.0,
500,211285,5,4,,103167833,4212,Unspecified,,,,,Inhibition of commercially obtained pure Drosophila Topoisomerase II in catalytic DNA unwinding.,Other,7473578.0,
501,212421,5,7,,103167833,4212,Unspecified,118828.0,,,,Inhibition of Taq polymerase at 10 uM (Slight inhibition),Other,9703471.0,
502,212547,5,7,,103167833,4212,Unspecified,118828.0,,,,Inhibition of Taq polymerase at 50 uM (Total inhibition),Other,9703471.0,
503,214778,4,4,,103167833,4212,Active,,,0.048,IC50,Anti-tumor activity against human UACC375 melanoma cell lines by using MTT assay,Confirmatory,7699715.0,
504,214779,4,4,,103167833,4212,Active,,,0.048,IC50,Antitumor activity against human melanoma UACC375 cell line.,Confirmatory,8960558.0,
505,215072,4,4,,103167833,4212,Active,,,0.027000000000000003,IC50,An average for IC50 values in the two solid tumor cell lines.,Confirmatory,8648600.0,
506,216273,6,2,,103167833,4212,Active,,,0.01,IC50,In vitro extracellular concentration required to reduce cell population to 50% against Walker 256 (WS) carcinoma cells,Confirmatory,1573635.0,
507,216434,4,4,,103167833,4212,Active,,,0.488,IC50,Tested for inhibitory activity against a multi drug resistant (MDR) strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).,Confirmatory,10956214.0,
508,216435,4,4,,103167833,4212,Active,,,0.008,IC50,Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).,Confirmatory,10956214.0,
509,216450,4,4,,103167833,4212,Active,,,1.4,IC50,Activity against resistant cell line of WiDr human colon tumor,Confirmatory,7699715.0,
510,216451,4,4,,103167833,4212,Active,,,0.01,IC50,Activity against sensitive cell line of WiDr human colon tumor,Confirmatory,7699715.0,
511,216573,4,4,,103167833,4212,Active,,,0.488,IC50,Tested against WiDr colon carcinoma (resistant) in the sulforhodamine B assay.,Confirmatory,8648600.0,
512,216575,4,4,,103167833,4212,Active,,,0.0081,IC50,Tested against WiDr colon (sensitive) in the sulforhodamine B assay.,Confirmatory,8648600.0,
513,216595,4,4,,103167833,4212,Active,,,0.0081,IC50,Activity against human colon carcinoma sensitive WiDr cell line.,Confirmatory,8960558.0,
514,216596,4,4,,103167833,4212,Active,,,0.488,IC50,Activity against human colon carcinoma multi drug resistant (MDR)-WiDr cell line.,Confirmatory,8960558.0,
515,219914,6,2,,103167833,4212,Active,,,0.01,IC50,Cytotoxicity against CHO cell line xrs6,Confirmatory,7473578.0,
516,220579,3,3,,103167833,4212,Unspecified,,,,,Binding affinity towards [poly(dA-dT)]2,Other,10411474.0,
517,220580,3,3,,103167833,4212,Unspecified,,,,,Binding affinity towards [poly(dG-dC)]2,Other,10411474.0,
518,221330,4,4,,103167833,4212,Active,,,0.003,IC50,"Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay.",Confirmatory,10956214.0,
519,222140,8,2,,103167833,4212,Unspecified,,,,,Inhibition of cellular growth was evaluated in vitro against human colon carcinoma LOVO.,Other,1875336.0,
520,222141,8,2,,103167833,4212,Unspecified,,,,,Inhibition of cellular growth was evaluated in vitro against human colon carcinoma subline resistant to DOXO (LOVO/DOXO).,Other,1875336.0,
521,223628,4,4,,103167833,4212,Active,,,0.006,IC50,"Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay.",Confirmatory,10956214.0,
522,226658,4,4,,103167833,4212,Active,,,0.021,IC50,An average for IC50 values in the two solid tumor cell lines and sensitive L1210 leukemia cell line.,Confirmatory,8648600.0,
523,227413,3,3,,103167833,4212,Unspecified,,,,,Dose modifying factor expressed as the ratio of IC50 for the chemotherapy drug to IC50 for drug + GG918; Range = 1.2-1850,Other,15012986.0,
524,227751,5,2,,103167833,4212,Inconclusive,,,,,Concentration required to reduce ethidium bromide fluorescence to 50% of control in presence of calf thymus DNA; ND is Not Determined.,Other,7525959.0,
525,230379,3,5,,103167833,4212,Unspecified,,,,,Resistance index measured as the ratio of IC50 of LoVo/Dx cell line to that of LoVo cell line.,Other,9876113.0,
526,230386,3,5,,103167833,4212,Unspecified,,,,,Resistance index as the ratio of IC50 value against LoVo/Dx to that of LoVo cell lines.,Other,7853345.0,
527,230412,3,3,,103167833,4212,Unspecified,,,,,It is the ratio of IC50 for LOVO tumor cell line to that of LOVO/DOXO cell line.,Other,1875336.0,
528,230914,3,3,,103167833,4212,Unspecified,,,,,Ratio of antilog(mean log IC50 in bone marrow sample) and antolog(mean log IC50) in HL-60),Other,10377219.0,
529,230915,3,3,,103167833,4212,Unspecified,,,,,Ratio of antilog(mean log IC50 in bone marrow sample) and antolog(mean log IC90) in HL-60),Other,10377219.0,
530,230916,3,3,,103167833,4212,Unspecified,,,,,Ratio of antilog(mean log IC90 in bone marrow sample) and antolog(mean log IC90) in HL-60),Other,10377219.0,
531,232016,3,3,,103167833,4212,Unspecified,,,,,Resistance index is the ratio of IC50 of resistant cell line/IC50 of sensitive cell line,Other,8145234.0,
532,232294,3,3,,103167833,4212,Unspecified,,,,,Differential cytotoxicity was determined from the ratio between BR1(IC50) and xrs-6 (IC50),Other,7525959.0,
533,232336,3,3,,103167833,4212,Unspecified,,,,,Ratio of BR1 IC50 to xrs-6 IC50,Other,7473578.0,
534,232611,4,3,,103167833,4212,Unspecified,,,,,Ratio of IC50 against V79 cells in the presence of air to that of nitrogen.,Other,7699696.0,
535,232808,3,4,,103167833,4212,Unspecified,,,,,The quotient of the IC50 in the myocytes divided by the mean IC50 in the three cell lines,Other,8960558.0,
536,232811,3,4,,103167833,4212,Unspecified,,,,,Toxicity ratio determined by the quotient of IC50 values in the myocytes divided by the average value in the three tumor lines.,Other,8648600.0,
537,232812,3,5,,103167833,4212,Unspecified,,,,,Toxicity ratio of quotient of the IC50 in myocytes divided by the average IC50 for three tumor cell lines,Other,7699715.0,
538,235123,3,3,,103167833,4212,Unspecified,,,,,Resistance index was determined by ratio of cytotoxicities of human colon adenocarcinoma (LoVo) cells to human colon adenocarcinoma resistant to doxorubicin (LoVo Dx) cells.,Other,10698460.0,
539,236269,5,3,,103167833,4212,Inconclusive,,,,,Fraction absorbed in human intestine after oral administration compound was measured; NA=Not available,Other,15658873.0,
540,236912,6,1,,103167833,4212,Unspecified,,,,,Permeability Coefficient in 2/4/A1 cell model,Other,15658873.0,
541,236913,6,1,,103167833,4212,Unspecified,,,,,Permeability Coefficient in Caco-2 cell culture model,Other,15658873.0,
542,236914,6,1,,103167833,4212,Unspecified,,,,,Permeability Coefficient in hexadecane membranes model,Other,15658873.0,
543,236916,6,1,,103167833,4212,Unspecified,,,,,Percentage of mass balance in hexadecane membranes model,Other,15658873.0,
544,240619,6,6,,103167833,4212,Unspecified,,,76.3,IC50,Inhibitory concentration against cytochrome P450 2D6,Confirmatory,15481972.0,
545,242838,7,1,,103167833,4212,Unspecified,,,,,Concentration required to displace ethidium from CT-DNA was determined from fluorescence binding studies,Other,15456268.0,
546,243266,3,4,,103167833,4212,Unspecified,,,,,Thermal denaturation of calf thymus DNA at 37 degree C,Other,15341949.0,
547,247764,6,2,,103167833,4212,Active,,,0.1,IC50,In vitro cytotoxicity against mouse leukemia L1210 cell lines,Confirmatory,15341949.0,
548,248010,4,4,,103167833,4212,Active,,,0.006999999999999999,IC50,Cytotoxicity against human PC3 cancer cell line was determined after 144 hr,Confirmatory,15456268.0,
549,248024,4,4,,103167833,4212,Active,,,0.0033,IC50,Cytotoxicity against human LoVo cancer cell line was determined after 144 hr,Confirmatory,15456268.0,
550,248039,4,3,,103167833,4212,Active,,,0.00075,IC50,Cytotoxicity against human H460M cancer cell line was determined after 144 hr,Confirmatory,15456268.0,
551,248040,5,3,,103167833,4212,Active,,,0.012,IC50,Cytotoxicity against human MKN45 cancer cell line was determined after 144 hr,Confirmatory,15456268.0,
552,248060,4,4,,103167833,4212,Active,,,0.0058,IC50,Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr,Confirmatory,15456268.0,
553,248858,4,4,,103167833,4212,Active,,,0.01,IC50,Cytotoxicity is determined as the concentration required to inhibit the growth of human colon adenocarcinoma (HT-29) cell line,Confirmatory,15456268.0,
554,253340,4,3,,103167833,4212,Active,,,0.075,IC50,Cytotoxicity against human PC3 cancer cell line was determined after 1 hr,Confirmatory,15456268.0,
555,253341,4,4,,103167833,4212,Active,,,0.012,IC50,Cytotoxicity against human LoVo cancer cell line was determined after 1 hr,Confirmatory,15456268.0,
556,253343,4,3,,103167833,4212,Active,,,0.00085,IC50,Cytotoxicity against human H460M cancer cell line was determined after 1 hr,Confirmatory,15456268.0,
557,253344,4,3,,103167833,4212,Active,,,0.0068,IC50,Cytotoxicity against human MKN45 cancer cell line was determined after 1 hr,Confirmatory,15456268.0,
558,253346,4,3,,103167833,4212,Active,,,0.11,IC50,Cytotoxicity against human HCT116 cancer cell line was determined after 1 hr,Confirmatory,15456268.0,
559,255441,3,4,,103167833,4212,Unspecified,,,,,Resistant factor as ability to overcome multidrug resistance of MES-SA/Dx5 cells compared to MES-SA cells,Other,16169719.0,
560,255777,6,2,,103167833,4212,Active,,,0.03,IC50,In vitro cytotoxicity variant MES-SA/Dx5 multidrug resistant cells,Confirmatory,16169719.0,
561,255789,6,2,,103167833,4212,Active,,,0.003,IC50,In vitro cytotoxicity against uterine sarcoma MES-SA cells,Confirmatory,16169719.0,
562,255803,6,2,,103167833,4212,Active,,,0.077,IC50,In vitro cytotoxicity against murine leukemia cell line L1210,Confirmatory,16169719.0,
563,255826,6,2,,103167833,4212,Active,,,0.02,IC50,In vitro cytotoxicity against colorectal adenocarcinoma HT-29 cells,Confirmatory,16169719.0,
564,270853,6,2,,103167833,4212,Active,,,0.025,IC50,Antiproliferative activity against HT29 cells by MTT assay after 72 hrs,Confirmatory,16824751.0,
565,270854,6,2,,103167833,4212,Active,,,0.003,IC50,Antiproliferative activity against MES-SA cells by MTT assay after 72 hrs,Confirmatory,16824751.0,
566,270855,6,3,,103167833,4212,Active,,,0.027999999999999997,IC50,Antiproliferative activity against doxorubicin-resistant MES-SA/Dx5 cells by MTT assay after 72 hrs,Confirmatory,16824751.0,
567,270856,3,5,,103167833,4212,Unspecified,,,,,"Resistant factor, IC50 for MES-SA/Dx5/ IC50 for MES-SA cells by MTT assay after 72 hrs",Other,16824751.0,
568,272491,4,5,,103167833,4212,Active,,,1.442,IC50,Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA,Confirmatory,17154505.0,
569,272492,4,5,,103167833,4212,Active,,,0.00035,IC50,Antiproliferative activity against MDA435/LCC6 cells by ELISA,Confirmatory,17154505.0,
570,272493,4,4,,103167833,4212,Active,,,0.395,IC50,Antiproliferative activity against adriamycin resistant P388 cells by ELISA,Confirmatory,17154505.0,
571,272494,4,4,,103167833,4212,Active,,,0.0043,IC50,Antiproliferative activity against P388 cells by ELISA,Confirmatory,17154505.0,
572,272510,4,5,,103167833,4212,Active,,,0.6459999999999999,IC50,"Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA",Confirmatory,17154505.0,
573,272511,4,5,,103167833,4212,Inconclusive,,,,IC50,Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM verapamil by ELISA,Confirmatory,17154505.0,
574,272512,3,5,,103167833,4212,Unspecified,,,,,"Relative fold, IC50 in absence to presence of 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane in multidrug resistant MDA435/LCC6 cells",Other,17154505.0,
575,272514,4,4,,103167833,4212,Active,,,0.19399999999999998,IC50,"Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA",Confirmatory,17154505.0,
576,272515,4,4,,103167833,4212,Inconclusive,,,,IC50,Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM verapamil by ELISA,Confirmatory,17154505.0,
577,272516,3,4,,103167833,4212,Unspecified,,,,,"Relative fold, IC50 in absence to presence of 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane in multidrug resistant P388 cells",Other,17154505.0,
578,280856,6,2,,103167833,4212,Active,,,0.96,IC50,Antiproliferative activity against human MDA-MB-231 cells by WST-1 method after 72 hrs,Confirmatory,17335189.0,
579,307325,6,2,,103167833,4212,Active,,,0.01,GI50,Growth inhibition of human HL60 cells by Almar blue assay,Confirmatory,17418582.0,
580,307326,6,2,,103167833,4212,Active,,,0.13,GI50,Growth inhibition of topoisomerase 2 mutated mitoxantrone-resistant MX2 cells by Alamar blue assay,Confirmatory,17418582.0,
581,307328,3,3,,103167833,4212,Unspecified,,,,,Ratio of GI50 for mitoxantrone-resistant human MX2 cells to GI50 for human HL60 cells,Other,17418582.0,
582,312292,6,2,,103167833,4212,Active,,,0.0026,IC50,Cytotoxicity against human K562 cells after 5 days by XTT assay,Confirmatory,18076140.0,
583,318700,6,3,,103167833,4212,Active,,,0.96,IC50,Antiproliferative activity against human MDA-MB-231 cells,Confirmatory,18296053.0,
584,320432,3,5,,103167833,4212,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as thermal denaturation temperature at 10 uM,Other,17962028.0,
585,320433,3,4,,103167833,4212,Unspecified,,,,,Cytotoxicity against human MCF7 cells at 4 ug/ml after 48 hrs by SRB assay,Other,17962028.0,
586,320434,3,4,,103167833,4212,Unspecified,,,,,Cytotoxicity against human NCI-H460 cells at 4 ug/ml after 48 hrs by SRB assay,Other,17962028.0,
587,320435,3,4,,103167833,4212,Unspecified,,,,,Cytotoxicity against human SF268 cells at 4 ug/ml after 48 hrs by SRB assay,Other,17962028.0,
588,320436,6,2,,103167833,4212,Active,,,0.78,GI50,Cytotoxicity against human PC3 cells after 48 hrs by SRB assay,Confirmatory,17962028.0,
589,320437,5,3,,103167833,4212,Active,,,0.00033,GI50,Cytotoxicity against human HL60 cells after 48 hrs by MTT assay,Confirmatory,17962028.0,
590,320438,5,3,,103167833,4212,Active,,,0.026000000000000002,GI50,Cytotoxicity against DNA topoisomerase-2 deficient human HL60/MX2 cells by MTT assay,Confirmatory,17962028.0,
591,320439,3,3,,103167833,4212,Unspecified,,,,,Ratio of GI50 for human HL60/MX2 cells to GI50 for human HL60 cells,Other,17962028.0,
592,320440,6,2,,103167833,4212,Active,,,3.93,GI50,Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay,Confirmatory,17962028.0,
593,320441,6,2,,103167833,4212,Active,,,1.29,GI50,Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay,Confirmatory,17962028.0,
594,320442,6,2,,103167833,4212,Active,,,0.97,GI50,Cytotoxicity against human SF268 cells after 48 hrs by SRB assay,Confirmatory,17962028.0,
595,322369,3,10,,103167833,4212,Unspecified,67462103.0,9429.0,,,Inhibition of human BCRP mediated mitoxantrone accumulation in wild type MCF7 cells at 5 uM by flow cytometry,Other,17964170.0,
596,322370,3,10,,103167833,4212,Unspecified,67462103.0,9429.0,,,Inhibition of human BCRP mediated mitoxantrone accumulation in mitoxantrone resistant MCF7 cells at 5 uM by flow cytometry,Other,17964170.0,
597,334268,6,2,,103167833,4212,Unspecified,,,,,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Other,12027731.0,
598,354538,3,4,,103167833,4212,Inactive,,,,,Cytotoxicity against rat C6 cells at 50 ug/mL to 2.5 mg/mL after 3 days treated 4 hrs before db-cAMP challenge by MTT assay,Other,8988604.0,
599,354542,3,4,,103167833,4212,Inactive,,,,,Inhibition of tubulin polymerization in rat C6 cells at 50 ug/mL to 2.5 mg/mL after 4 hrs,Other,8988604.0,
600,354543,3,4,,103167833,4212,Inactive,,,,,Cytotoxicity against rat C6 cells assessed as cell release at 50 ug/mL to 2.5 mg/mL after 5 hrs by MTT assay in absence of db-cAMP,Other,8988604.0,
601,363203,5,3,,103167833,4212,Active,,,0.04786,GI50,Antitumor activity against human NCI60 cells after 48 hrs by SRB assay,Confirmatory,18715786.0,
602,364460,6,2,,103167833,4212,Active,,,0.1,IC50,Cytotoxicity against human HeLa cells expressing telomerase after 96 hrs by MTT assay,Confirmatory,18754611.0,
603,364461,6,3,,103167833,4212,Active,,,0.1,IC50,Cytotoxicity against human 293T cells expressing telomerase after 96 hrs by MTT assay,Confirmatory,18754611.0,
604,375433,9,5,,103167833,4212,Unspecified,21263835.0,64805.0,10.0,Ki,Displacement of [3H]PSB0413 from human platelet P2Y12 receptor,Confirmatory,19463000.0,
605,375434,4,7,,103167833,4212,Unspecified,21263835.0,64805.0,,,Displacement of [3H]PSB0413 from human platelet P2Y12 receptor at 10 uM,Other,19463000.0,
606,380011,6,2,,103167833,4212,Unspecified,,,,,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Other,10843567.0,
607,380012,6,2,,103167833,4212,Unspecified,,,,,Cytotoxicity against human HL60 cells after 48 hrs by MTT assay,Other,10843567.0,
608,380013,6,3,,103167833,4212,Unspecified,,,,,Cytotoxicity against human HCT cells after 48 hrs by MTT assay,Other,10843567.0,
609,380014,6,3,,103167833,4212,Unspecified,,,,,Cytotoxicity against human MKN28 cells after 48 hrs by MTT assay,Other,10843567.0,
610,381805,3,5,,103167833,4212,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as change in thermal stability at 2 uM in tris-HCl buffer at pH 7.5 by thermal denaturation assay,Other,18258442.0,
611,381806,6,2,,103167833,4212,Active,,,0.42,IC50,Growth inhibition of human K562 cells after 72 hrs by MTS method,Confirmatory,18258442.0,
612,381807,6,2,,103167833,4212,Active,,,1.68,IC50,Growth inhibition of etoposide-resistant human K/VP.5 cells after 72 hrs by MTS method,Confirmatory,18258442.0,
613,381808,3,4,,103167833,4212,Unspecified,,,,,"Resistance factor, ratio of IC50 for etoposide-resistant human K/VP.5 cells to IC50 for human K562 cells",Other,18258442.0,
614,381809,9,5,,103167833,4212,Active,13959709.0,7153.0,5.3,IC50,Inhibition of human topoisomerase 2alpha decantation activity,Confirmatory,18258442.0,
615,395134,3,4,,103167833,4212,Unspecified,,,,,Binding affinity to poly(dA).poly(dT) DNA assessed as change in melting temperature,Other,18403056.0,
616,404304,3,10,,103167833,4212,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
617,404699,6,2,,103167833,4212,Active,,,0.063,IC50,Cytotoxicity against human mitoxantrone-sensitive HL60 cells after 72 hrs,Confirmatory,18507368.0,
618,404700,6,3,,103167833,4212,Active,,,1.51,IC50,Cytotoxicity against mitoxantrone-resistant human HL60/MX2 cells after 72 hrs,Confirmatory,18507368.0,
619,404701,3,3,,103167833,4212,Unspecified,,,,,"Resistant index, ratio of IC50 for mitoxantrone-resistant human HL60/MX2 cells to IC50 for mitoxantrone-sensitive human HL60 cells",Other,18507368.0,
620,409954,4,9,,103167833,4212,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
621,425652,7,2,,103167833,4212,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
622,425653,7,2,,103167833,4212,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
623,429649,6,2,,103167833,4212,Active,,,8.0,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,19615900.0,
624,429650,6,2,,103167833,4212,Active,,,6.3,IC50,Cytotoxicity against human HL60 cells by MTT assay,Confirmatory,19615900.0,
625,429651,6,2,,103167833,4212,Active,,,8.7,IC50,Cytotoxicity against human HT-29 cells by MTT assay,Confirmatory,19615900.0,
626,429709,6,2,,103167833,4212,Active,,,7.1,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,19615900.0,
627,429710,6,2,,103167833,4212,Active,,,9.8,IC50,Cytotoxicity against human SKOV3 cells by MTT assay,Confirmatory,19615900.0,
628,429711,6,2,,103167833,4212,Active,,,6.2,IC50,Cytotoxicity against human U937 cells by MTT assay,Confirmatory,19615900.0,
629,431398,7,2,,103167833,4212,Unspecified,,,,EC50,Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay,Confirmatory,19743858.0,
630,431399,7,3,,103167833,4212,Unspecified,,,,EC50,Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay,Confirmatory,19743858.0,
631,431400,3,3,,103167833,4212,Unspecified,,,,,Ratio of GI50 for human HL60/MX2 cells to GI50 for human HL60 cells,Other,19743858.0,
632,434959,1,1,,85788828,4212,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
633,436862,5,2,,103167833,4212,Active,,,0.63,IC50,Inhibition of VIM2 using nitrocefin as substrate after 15 mins by microtiter plate assay,Confirmatory,19553129.0,
634,436864,5,2,,103167833,4212,Unspecified,,,56.0,IC50,Inhibition of IMP1 using nitrocefin as substrate after 15 mins by microtiter plate assay,Confirmatory,19553129.0,
635,436865,5,2,,103167833,4212,Inconclusive,,,,IC50,Inhibition of VIM2 using CCF2 as substrate after 15 mins by FRET assay,Confirmatory,19553129.0,
636,436867,5,2,,103167833,4212,Active,,,1.5,Ki,Inhibition of VIM2 using nitrocefin as substrate by rapid dilution method,Confirmatory,19553129.0,
637,436868,3,3,,103167833,4212,Unspecified,,,,,Inhibition of VIM2 using nitrocefin as substrate at 44 uM after 15 mins by microtiter plate assay,Other,19553129.0,
638,436872,3,3,,103167833,4212,Unspecified,,,,,Inhibition of IMP1 using nitrocefin as substrate at 56 uM after 15 mins by microtiter plate assay,Other,19553129.0,
639,436874,5,2,,103167833,4212,Unspecified,,,25.0,IC50,Inhibition of TEM-1 using nitrocefin as substrate after 15 mins by microtiter plate assay,Confirmatory,19553129.0,
640,436875,3,3,,103167833,4212,Unspecified,,,,,Inhibition of TEM-1 using nitrocefin as substrate at 25 uM after 15 mins by microtiter plate assay,Other,19553129.0,
641,436876,5,2,,103167833,4212,Unspecified,,,25.0,IC50,Inhibition of Enterobacter cloacae AmpC using nitrocefin as substrate after 15 mins by microtiter plate assay,Confirmatory,19553129.0,
642,436877,3,3,,103167833,4212,Unspecified,,,,,Inhibition of Enterobacter cloacae AmpC using nitrocefin as substrate at 25 uM after 15 mins by microtiter plate assay,Other,19553129.0,
643,436878,7,2,,103167833,4212,Unspecified,,,,,Antibacterial activity against imipenem-non resistant Escherichia coli BL21(DE3) after 18 hrs by twofold serial broth dilution method,Other,19553129.0,
644,436879,7,2,,103167833,4212,Unspecified,,,,,Antibacterial activity against imipenem-resistant Escherichia coli BL21(DE3) expressing VIM2 gene after 18 hrs by twofold serial broth dilution method,Other,19553129.0,
645,436881,3,4,,103167833,4212,Active,,,,,Inhibition of VIM2 in imipenem-resistant Escherichia coli BL21(DE3) assessed as potentiation of imipenem-induced bactericidal activity at 50 uM after 18 hrs by twofold serial broth dilution method,Other,19553129.0,
646,436883,3,3,,103167833,4212,Active,,,,,Inhibition of VIM2 in imipenem-resistant Escherichia coli BL21(DE3) assessed as potentiation of imipenem-induced bactericidal activity at 2.1 ug/mL after 18 hrs by checkerboard microdilution method,Other,19553129.0,
647,436884,3,3,,103167833,4212,Inactive,,,,,Bactericidal activity against imipenem-resistant Escherichia coli BL21(DE3) expressing VIM2 gene at 2.1 ug/mL after 24 hrs by broth microdilution method,Other,19553129.0,
648,436885,3,3,,103167833,4212,Inactive,,,,,Bactericidal activity against imipenem-non resistant Escherichia coli BL21(DE3) at 2.1 ug/mL after 24 hrs by broth microdilution method,Other,19553129.0,
649,436892,3,3,,103167833,4212,Inactive,,,,,Bacteriostatic activity against imipenem-resistant Escherichia coli BL21(DE3) expressing VIM2 gene at 2.1 ug/mL after 24 hrs by broth microdilution method,Other,19553129.0,
650,436893,3,3,,103167833,4212,Inactive,,,,,Bacteriostatic activity against imipenem-non resistant Escherichia coli BL21(DE3) at 2.1 ug/mL after 24 hrs by broth microdilution method,Other,19553129.0,
651,436895,3,3,,103167833,4212,Active,,,,,Inhibition of VIM2 in imipenem-resistant Escherichia coli BL21(DE3) assessed as potentiation of imipenem-induced bactericidal activity at 8.4 ug/mL after 18 hrs by checkerboard microdilution method,Other,19553129.0,
652,436896,3,3,,103167833,4212,Active,,,,,Inhibition of VIM2 in imipenem-resistant Escherichia coli BL21(DE3) assessed as potentiation of imipenem-induced bactericidal activity at 4.2 ug/mL after 18 hrs by checkerboard microdilution method,Other,19553129.0,
653,437514,5,2,,103167833,4212,Active,,,0.89,EC50,Displacement of fluorescent pyrene-neomycin conjugate from tau stem-loop RNA,Confirmatory,19839622.0,
654,437515,5,2,,103167833,4212,Active,,,0.46,IC50,Binding affinity to tau stem-loop RNA assessed as inhibition of RNA stem-loop unfolding,Confirmatory,19839622.0,
655,455589,5,2,,103167833,4212,Active,,,6.8,IC50,Cytotoxicity against human HL60 cells by MTT assay,Confirmatory,19926279.0,
656,463106,1,2,,90341083,4212,Inconclusive,188528692.0,9099.0,14.6892,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
657,466796,5,2,,103167833,4212,Active,,,7.8,GI50,Growth inhibition of human HL60 cells by MTT assay,Confirmatory,20153184.0,
658,466797,5,2,,103167833,4212,Active,,,11.0,GI50,Growth inhibition of human SKOV3 cells by MTT assay,Confirmatory,20153184.0,
659,466798,5,2,,103167833,4212,Active,,,8.3,GI50,Growth inhibition of human A549 cells by MTT assay,Confirmatory,20153184.0,
660,466799,5,2,,103167833,4212,Active,,,8.9,GI50,Growth inhibition of human HT-29 cells by MTT assay,Confirmatory,20153184.0,
661,477016,3,3,,103167833,4212,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as temperature required to cause 50% of DNA denatured at 10 uM by thermal denaturation assay,Other,20064676.0,
662,477017,3,3,,103167833,4212,Inconclusive,,,,,Displacement of ethidium bromide from calf thymus DNA assessed as decrease of fluorescence of bound ethidium bromide by fluorometric assay,Other,20064676.0,
663,477295,3,3,,103167833,4212,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,20106561.0,
664,485281,1,1,,11111483,4212,Inconclusive,254220970.0,,11.2202,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
665,485290,1,1,,11111483,4212,Inactive,20150581.0,,19.9526,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
666,485295,1,2,,90341083,4212,Active,30027657.0,,1.5003,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
667,485297,1,1,,90341083,4212,Inactive,4759012.0,9367.0,91.9997,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
668,485298,1,1,,90341083,4212,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
669,485313,1,2,,90341083,4212,Inactive,255652944.0,4864.0,115.821,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
670,485342,1,2,,90341083,4212,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
671,485345,1,2,,90341083,4212,Inconclusive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
672,485366,1,2,,90341083,4212,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
673,485368,1,2,,90341083,4212,Inconclusive,72386991.0,3656265.0,4.7755,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
674,487000,3,3,,103167833,4212,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as ratio of final absorbance area to the absorbance at 100 uM after 24 hrs by UV spectrophotometer analysis relative to control,Other,20471844.0,
675,488772,1,1,,90341083,4212,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
676,488773,1,2,,90341083,4212,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
677,488816,1,1,,90341083,4212,Active,4758356.0,2237.0,2.9935,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
678,488837,1,1,,90341083,4212,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
679,488839,1,1,,92763439,4212,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
680,488839,1,1,,92763439,4212,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
681,488862,1,1,,92763439,4212,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
682,488895,1,2,,92763439,4212,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
683,488896,1,1,,92763439,4212,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
684,488899,1,1,,92763439,4212,Active,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
685,488949,1,2,,90341083,4212,Active,41055989.0,54737.0,6.7016,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
686,488953,1,1,,90341083,4212,Active,187960037.0,10951.0,5.6234,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
687,488965,1,2,,92763439,4212,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
688,488966,1,1,,92763439,4212,Active,,,211.07,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
689,488978,1,1,,90341083,4212,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
690,488981,1,1,,90341083,4212,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
691,488982,1,1,,90341083,4212,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
692,488983,1,1,,90341083,4212,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
693,492953,1,1,,92763439,4212,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
694,492956,1,1,,92763439,4212,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
695,492961,1,1,,11111483,4212,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
696,492972,1,1,,92763439,4212,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
697,493005,1,1,,92763439,4212,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
698,493008,1,1,,92763439,4212,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
699,493008,1,1,,92763439,4212,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
700,493008,1,1,,92763439,4212,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
701,493008,1,1,,92763439,4212,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
702,493020,1,1,,92763439,4212,Active,,,0.38,CC50,Cytotoxicity screening for potential Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
703,493087,1,1,,92763439,4212,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
704,493091,1,1,,92763439,4212,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
705,493098,1,1,,92763439,4212,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
706,493106,1,1,,90341083,4212,Inactive,116283940.0,79915.0,32.6294,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
707,493107,1,1,,90341083,4212,Active,116283940.0,79915.0,4.609,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
708,493131,1,1,,92763439,4212,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
709,493153,1,1,,90341083,4212,Inconclusive,,4780.0,14.581,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
710,493153,1,1,,90341083,4212,Inconclusive,224028257.0,4780.0,14.581,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
711,493160,1,1,,92763439,4212,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
712,493164,1,2,,90341083,4212,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
713,493164,1,2,,90341083,4212,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
714,493164,1,2,,90341083,4212,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
715,493187,1,2,,92763439,4212,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
716,493199,1,1,,11111483,4212,Active,41281591.0,4154.0,0.8784,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding: Initial hit validation from the primary screen,Confirmatory,,
717,493205,1,1,,11111483,4212,Inconclusive,41281591.0,4154.0,9.8562,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding: Initial hit validation in AlphaScreen assay for MBNL1-(CUG)12 binding,Confirmatory,,
718,493244,1,1,,92763439,4212,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
719,493244,1,1,,92763439,4212,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
720,493244,1,1,,92763439,4212,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
721,493244,1,1,,92763439,4212,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
722,504326,1,2,,92763439,4212,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
723,504326,1,2,,92763439,4212,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
724,504327,1,1,,11111483,4212,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
725,504327,1,1,,90341083,4212,Inconclusive,153791535.0,2648.0,25.1189,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
726,504329,1,1,,92763439,4212,Active,227977143.0,23308111.0,2.049,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
727,504332,1,1,,11111483,4212,Active,168985070.0,,3.9811,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
728,504332,1,1,,90341083,4212,Active,168985070.0,,8.4368,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
729,504339,1,1,,92763439,4212,Active,162330054.0,,6.3096,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
730,504357,1,1,,92763439,4212,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
731,504357,1,1,,92763439,4212,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
732,504411,1,1,,92763439,4212,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
733,504414,1,1,,92763439,4212,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
734,504414,1,1,,92763439,4212,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
735,504423,1,1,,92763439,4212,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
736,504441,1,1,,92763439,4212,Active,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
737,504444,1,1,,92763439,4212,Inconclusive,224028257.0,4780.0,8.1995,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
738,504454,1,3,,92763439,4212,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
739,504462,1,1,,92763439,4212,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
740,504490,1,2,,92763439,4212,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
741,504523,1,1,,92763439,4212,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
742,504523,1,1,,92763439,4212,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
743,504536,1,1,,90341083,4212,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
744,504538,1,1,,104223109,4212,Inactive,,,,IC50,Screening for Inhibitors of Bacterial Capsule Biogenesis - T7 Lysis Inhibition (2),Confirmatory,,
745,504543,1,1,,104223109,4212,Active,,,201.0,IC50,Screening for Inhibitors of Bacterial Capsule Biogenesis E.coli strain UT189 with C7 control (2),Confirmatory,,
746,504547,1,1,,90341083,4212,Inconclusive,115503961.0,4357161.0,21.3313,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
747,504548,1,2,,90341083,4212,Inconclusive,157877932.0,5655980.0,23.9341,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
748,504558,1,1,,92763439,4212,Active,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
749,504577,2,2,,92763439,4212,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
750,504582,2,1,,92763439,4212,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
751,504621,1,1,,92763439,4212,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
752,504634,1,1,,92763439,4212,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
753,504648,1,1,,92763439,4212,Active,,,12.9953,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
754,504690,1,3,,92763439,4212,Active,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
755,504692,2,2,,92763439,4212,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
756,504700,1,1,,92763439,4212,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
757,504700,1,1,,92763439,4212,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
758,504707,1,1,,92763439,4212,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
759,504707,1,1,,92763439,4212,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
760,504720,1,1,,92763439,4212,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
761,504725,1,1,,92763439,4212,Inactive,312275222.0,,,AC50_uM,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
762,504726,1,1,,92763439,4212,Active,312275222.0,,4.075,AC50_uM,24 hour HeLa Cytotox assay Measured in Cell-Based System Using Plate Reader - 2117-03_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
763,504727,1,1,,92763439,4212,Active,312275222.0,,2.316,AC50_uM,C-LANA Counter Screen: DNA intercalators Measured in Biochemical System Using Plate Reader - 2117-02_Inhibitor_Dose_CherryPick_Activity_Set2,Confirmatory,,
764,504734,1,1,,92763439,4212,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
765,504749,1,3,,11111483,4212,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
766,504749,1,3,1.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
767,504749,1,3,2.0,11111483,4212,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
768,504749,1,3,3.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
769,504749,1,3,4.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
770,504749,1,3,5.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
771,504749,1,3,6.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
772,504749,1,3,7.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
773,504749,1,3,8.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
774,504749,1,3,9.0,11111483,4212,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
775,504749,1,3,10.0,11111483,4212,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
776,504749,1,3,11.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
777,504749,1,3,12.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
778,504749,1,3,13.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
779,504749,1,3,14.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
780,504749,1,3,15.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
781,504749,1,3,16.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
782,504749,1,3,17.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
783,504749,1,3,18.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
784,504749,1,3,19.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
785,504749,1,3,20.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
786,504749,1,3,21.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
787,504749,1,3,22.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
788,504749,1,3,23.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
789,504749,1,3,24.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
790,504749,1,3,25.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
791,504749,1,3,26.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
792,504749,1,3,27.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
793,504749,1,3,28.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
794,504749,1,3,29.0,11111483,4212,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
795,504749,1,3,30.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
796,504749,1,3,31.0,11111483,4212,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
797,504749,1,3,32.0,11111483,4212,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
798,504749,1,3,33.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
799,504749,1,3,34.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
800,504749,1,3,35.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
801,504749,1,3,36.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
802,504749,1,3,37.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
803,504749,1,3,38.0,11111483,4212,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
804,504749,1,3,39.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
805,504749,1,3,40.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
806,504749,1,3,41.0,11111483,4212,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
807,504749,1,3,42.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
808,504749,1,3,43.0,11111483,4212,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
809,504749,1,3,44.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
810,504749,1,3,45.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
811,504749,1,3,46.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
812,504749,1,3,47.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
813,504749,1,3,48.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
814,504749,1,3,49.0,11111483,4212,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
815,504749,1,3,50.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
816,504749,1,3,51.0,11111483,4212,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
817,504749,1,3,52.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
818,504749,1,3,53.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
819,504749,1,3,54.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
820,504749,1,3,55.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
821,504749,1,3,56.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
822,504749,1,3,57.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
823,504749,1,3,58.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
824,504749,1,3,59.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
825,504749,1,3,60.0,11111483,4212,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
826,504749,1,3,61.0,11111483,4212,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
827,504753,1,2,,92763439,4212,Inactive,12381848.0,,,,Single concentration confirmation of uHTS small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
828,504766,2,1,,92763439,4212,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
829,504775,1,1,,92763439,4212,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
830,504803,1,1,,92763439,4212,Active,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
831,504810,1,2,,90341083,4212,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
832,504812,1,2,,90341083,4212,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
833,504832,1,1,,11111483,4212,Active,,,2.8695,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
834,504834,1,1,,11111483,4212,Active,,,1.6137,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
835,504836,1,2,,90341083,4212,Inconclusive,168984549.0,,2.3281,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
836,504845,1,1,,90341083,4212,Active,86301163.0,5999.0,11.9173,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
837,504845,1,1,,92763439,4212,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
838,504847,1,1,,11111483,4212,Inconclusive,63054845.0,7421.0,8.9125,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
839,504847,1,1,,90341083,4212,Inconclusive,63054845.0,7421.0,7.9433,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
840,504847,1,1,,92763439,4212,Inconclusive,63054845.0,7421.0,100.0,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
841,504865,1,1,,11111483,4212,Inconclusive,118600387.0,7398.0,35.4813,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
842,504865,1,1,,90341083,4212,Inconclusive,118600387.0,7398.0,79.4328,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
843,504884,1,2,,92763439,4212,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
844,504891,1,1,,92763439,4212,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
845,504894,1,1,,92763439,4212,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
846,504926,1,1,,99234132,4212,Inactive,,,,,Counter screen assessing cytotoxicity of powder sourced compounds from high-throughput yeast screen for caloric restriction mimetics that inhibit age-related superoxide.,Other,,
847,504931,1,1,,99234132,4212,Active,,,3.41,EC50_MICROM,Confirmation dose response of powder sourced compounds for HTS of caloric restriction mimetics that inhibit age-related superoxide.,Confirmatory,,
848,504936,1,1,,99234132,4212,Inactive,,,,,High throughput DNA content assay for compounds that induce DNA replication stress in Saccharomyces cerevisiae,Other,,
849,504937,1,2,,92763439,4212,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
850,521220,3,3,,103167833,4212,Active,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
851,524790,7,2,,103167833,4212,Active,,,0.00059,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
852,524791,7,2,,103167833,4212,Active,,,0.00093,IC50,Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
853,524792,7,2,,103167833,4212,Active,,,0.00148,IC50,Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
854,524793,7,2,,103167833,4212,Active,,,0.001,IC50,Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
855,524794,7,1,,103167833,4212,Active,,,0.00141,IC50,Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
856,524795,7,2,,103167833,4212,Active,,,0.0008300000000000001,IC50,Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
857,524796,7,1,,103167833,4212,Active,,,0.00112,IC50,Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
858,536039,4,2,,103167833,4212,Active,,,0.063,IC50,Cytotoxicity against human HL60 cells after 72 hrs,Confirmatory,20961767.0,
859,536040,4,3,,103167833,4212,Active,,,1.51,IC50,Cytotoxicity against human HL60/MX2 cells after 72 hrs,Confirmatory,20961767.0,
860,536041,2,3,,103167833,4212,Unspecified,,,,,"Resistance index, ratio of IC50 for human HL60/MX2 cells to IC50 for human HL60 cells",Other,20961767.0,
861,537733,2,3,,103167833,4212,Inactive,,,,,Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,Other,20739103.0,
862,537734,5,2,,103167833,4212,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay,Other,20739103.0,
863,537735,2,3,,103167833,4212,Active,,,,,Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,Other,20739103.0,
864,537736,5,2,,103167833,4212,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay,Other,20739103.0,
865,538150,1,4,,103167833,4212,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as ratio of final absorbance area to absorbance of compound at 100 uM after 24 hrs by UV spectrophotometer analysis,Other,20846761.0,
866,538479,4,2,,103167833,4212,Active,,,7.5,IC50,Cytotoxicity against human HL60 cells by MTT assay,Confirmatory,20951582.0,
867,538480,4,2,,103167833,4212,Active,,,3.96,IC50,Cytotoxicity against human HCT116 cells by MTT assay,Confirmatory,20951582.0,
868,540209,4,3,,103167833,4212,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
869,540210,4,3,,103167833,4212,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
870,540211,2,5,,103167833,4212,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
871,540212,4,3,,103167833,4212,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
872,540213,4,3,,103167833,4212,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
873,540248,1,1,,92763439,4212,Active,121945198.0,,,,Fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of the HTRA serine peptidase 1 (HTRA1),Other,,
874,540253,1,1,,92763439,4212,Inconclusive,5031833.0,10073.0,31.6228,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
875,540253,1,1,,92763439,4212,Inconclusive,5453555.0,5901.0,31.6228,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
876,540253,1,1,,92763439,4212,Inconclusive,19923142.0,3837.0,31.6228,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
877,540254,1,2,,92763439,4212,Inactive,,,,IC50,Discovery of Small Molecule Probes for H1N1 NS1a - H1N1 (KY180) Influenza Antiviral Screen,Confirmatory,,
878,540256,1,2,,90341083,4212,Inconclusive,,,0.0651,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
879,540256,1,2,,92763439,4212,Active,,,0.5012,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
880,540257,1,2,,92763439,4212,Inactive,,,,IC50,Discovery of Small Molecule Probes for H1N1 NS1a - H1N1 (KY136) Influenza Antiviral Screen,Confirmatory,,
881,540263,1,1,,92763439,4212,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
882,540263,1,1,,92763439,4212,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
883,540267,1,1,,92763439,4212,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
884,540276,1,2,,11111482,4212,Inconclusive,420597.0,,0.3263,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
885,540276,1,2,,11111483,4212,Inconclusive,420597.0,,0.3263,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
886,540276,1,2,,50111146,4212,Inconclusive,420597.0,,0.3263,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
887,540276,1,2,,90341083,4212,Inconclusive,420597.0,,0.3263,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
888,540276,1,2,,92763439,4212,Inconclusive,420597.0,,0.1,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
889,540295,1,1,,92763439,4212,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
890,540303,1,1,,92763439,4212,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
891,540303,1,1,,92763439,4212,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
892,540303,1,1,,92763439,4212,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
893,540308,1,1,,92763439,4212,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
894,540317,1,1,,92763439,4212,Active,187960037.0,10951.0,25.1189,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
895,540336,1,1,,92763439,4212,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
896,540336,1,1,,92763439,4212,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
897,540364,1,2,,92763439,4212,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
898,562240,5,2,,103167833,4212,Active,,,21.84,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry,Confirmatory,19786608.0,
899,562241,5,2,,103167833,4212,Active,,,9.7,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry,Confirmatory,19786608.0,
900,562242,5,2,,103167833,4212,Active,,,5.02,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry,Confirmatory,19786608.0,
901,562243,5,2,,103167833,4212,Active,,,21.84,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay,Confirmatory,19786608.0,
902,562244,5,2,,103167833,4212,Active,,,9.7,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay,Confirmatory,19786608.0,
903,562245,5,2,,103167833,4212,Active,,,5.02,IC50,Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay,Confirmatory,19786608.0,
904,567091,2,6,,103167833,4212,Unspecified,,,,,Drug absorption in human assessed as human intestinal absorption rate,Other,21112128.0,
905,588211,2,3,,103167833,4212,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
906,588212,2,3,,103167833,4212,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
907,588213,2,3,,103167833,4212,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
908,588214,2,3,,103167833,4212,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
909,588215,2,3,,103167833,4212,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
910,588216,2,3,,103167833,4212,Active,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
911,588217,2,3,,103167833,4212,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
912,588218,2,3,,103167833,4212,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
913,588219,2,3,,103167833,4212,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
914,588335,1,1,,92763439,4212,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
915,588345,1,1,,92763439,4212,Active,6978787.0,25255.0,1.248,AC50_uM,MLPCN Dyrk1A Kinase Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
916,588348,1,1,,92763439,4212,Inactive,,,,AC50_uM,MLPCN Dyrk1A Artifact Assay Measured in Biochemical System Using Plate Reader - 2124-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
917,588349,1,1,,90341083,4212,Inconclusive,,,19.9526,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
918,588352,1,2,,92763439,4212,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
919,588354,1,1,,92763439,4212,Active,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
920,588358,1,2,,92763439,4212,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
921,588378,1,1,,90341083,4212,Inconclusive,171543895.0,6311.0,0.3162,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
922,588391,1,1,,92763439,4212,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
923,588405,1,1,,92763439,4212,Active,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
924,588413,1,2,,92763439,4212,Active,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
925,588436,1,1,,92763439,4212,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
926,588453,1,1,,90341083,4212,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
927,588453,1,1,,92763439,4212,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
928,588456,1,1,,90341083,4212,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
929,588456,1,1,,92763439,4212,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
930,588458,1,1,,92763439,4212,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
931,588473,1,1,,92763439,4212,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
932,588473,1,1,,92763439,4212,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
933,588475,1,2,,92763439,4212,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
934,588475,1,2,,92763439,4212,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
935,588489,1,1,,92763439,4212,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
936,588492,1,1,,92763439,4212,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
937,588493,1,2,,92763439,4212,Active,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
938,588497,1,2,,92763439,4212,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
939,588497,1,2,,92763439,4212,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
940,588497,1,2,,92763439,4212,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
941,588499,1,3,,92763439,4212,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
942,588499,1,3,,92763439,4212,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
943,588499,1,3,,92763439,4212,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
944,588501,1,2,,92763439,4212,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
945,588501,1,2,,92763439,4212,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
946,588501,1,2,,92763439,4212,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
947,588549,1,1,,92763439,4212,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
948,588579,1,1,,11111483,4212,Active,7705344.0,51426.0,1.3371,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
949,588579,1,1,,90341083,4212,Active,7705344.0,51426.0,2.6679,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
950,588579,1,1,,92763439,4212,Active,7705344.0,51426.0,25.1189,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
951,588590,1,1,,92763439,4212,Active,154350220.0,11201.0,11.2202,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
952,588591,1,1,,92763439,4212,Active,5729982.0,5429.0,3.1623,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
953,588621,1,1,,92763439,4212,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
954,588664,1,2,,92763439,4212,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
955,588664,1,2,,92763439,4212,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
956,588674,1,2,,92763439,4212,Active,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
957,588689,1,1,,92763439,4212,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
958,588692,2,1,,92763439,4212,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
959,588726,1,2,,92763439,4212,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
960,588727,1,1,,92763439,4212,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
961,588795,1,1,,90341083,4212,Active,4758356.0,2237.0,2.9935,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
962,588795,1,1,,92763439,4212,Active,4758356.0,2237.0,2.8184,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
963,588814,1,3,,92763439,4212,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
964,588819,1,4,,92763439,4212,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
965,588820,1,1,,92763439,4212,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based high throughput confirmation assay for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1).,Screening,,
966,588824,1,1,,92763439,4212,Inactive,9629429.0,,,,Counterscreen for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1): Luminescence-based cell-based high throughput assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16).,Screening,,
967,588850,1,1,,92763439,4212,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
968,588852,1,3,,92763439,4212,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
969,588855,1,1,,92763439,4212,Active,18418623.0,4088.0,1.5849,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
970,588856,1,1,,92763439,4212,Inactive,,,7.0795,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
971,588975,1,10,,103167833,4212,Unspecified,67462103.0,9429.0,,,"Substrates of transporters of clinical importance in the absorption and disposition of drugs, BCRP",Other,20190787.0,
972,588977,1,10,,103167833,4212,Unspecified,308153583.0,1244.0,,,"Substrates of transporters of clinical importance in the absorption and disposition of drugs, MRP2",Other,20190787.0,
973,589896,3,2,,103167833,4212,Active,,,7.83,IC50,Cytotoxicity against human A549 cells after 72 hrs,Confirmatory,21354791.0,
974,589897,3,2,,103167833,4212,Active,,,8.1,IC50,Cytotoxicity against human HL60 cells after 72 hrs,Confirmatory,21354791.0,
975,591075,3,2,,103167833,4212,Active,,,0.063,IC50,Cytotoxicity against human HL60 cells,Confirmatory,21439821.0,
976,591076,3,3,,103167833,4212,Active,,,1.51,IC50,Cytotoxicity against human HL60/MX2 cells,Confirmatory,21439821.0,
977,591077,1,3,,103167833,4212,Unspecified,,,,,"Resistance index, ratio IC50 for human HL60/MX2 cells to IC50 for human HL60 cells",Other,21439821.0,
978,592673,3,2,,103167833,4212,Active,,,7.9,IC50,Cytotoxicity against human HL60 cells by MTT assay,Confirmatory,21458279.0,
979,592674,3,2,,103167833,4212,Active,,,7.8,IC50,Cytotoxicity against human A549 cells by MTT assay,Confirmatory,21458279.0,
980,592675,3,2,,103167833,4212,Active,,,7.2,IC50,Cytotoxicity against human HCT116 cells by MTT assay,Confirmatory,21458279.0,
981,592676,3,2,,103167833,4212,Active,,,7.1,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,21458279.0,
982,594147,4,3,,103167833,4212,Unspecified,,,,,Antiproliferative activity against human KB/HeLa cells after 48 hrs by XTT assay,Other,21458262.0,
983,594148,4,2,,103167833,4212,Unspecified,,,,,Antiproliferative activity against human SKOV3 cells after 48 hrs by XTT assay,Other,21458262.0,
984,594149,4,2,,103167833,4212,Unspecified,,,,,Antiproliferative activity against human SF268 cells after 48 hrs by XTT assay,Other,21458262.0,
985,594150,4,2,,103167833,4212,Unspecified,,,,,Antiproliferative activity against human NCI-H460 cells after 48 hrs by XTT assay,Other,21458262.0,
986,594151,4,3,,103167833,4212,Unspecified,,,,,Antiproliferative activity against human RKOp27 cells after 48 hrs by XTT assay,Other,21458262.0,
987,594152,4,3,,103167833,4212,Unspecified,,,,,Antiproliferative activity against human RKOp27IND cells after 48 hrs by XTT assay,Other,21458262.0,
988,595061,3,2,,103167833,4212,Active,,,0.022000000000000002,IC50,Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay,Confirmatory,21444205.0,
989,595062,3,3,,103167833,4212,Active,,,0.012,IC50,Cytotoxicity against human MES-SA cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay,Confirmatory,21444205.0,
990,595063,3,3,,103167833,4212,Active,,,0.08,IC50,Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay,Confirmatory,21444205.0,
991,595064,1,4,,103167833,4212,Unspecified,,,,,"Resistant factor, ratio of IC50 for doxorubicin-resistant human MES-SA/Dx5 cells to IC50 for doxorubicin-sensitive human MES-SA cells",Other,21444205.0,
992,602039,3,2,,103167833,4212,Active,,,7.8,IC50,Cytotoxicity against human A549 cells after 24 hrs by MTT assay,Confirmatory,21507644.0,
993,602040,3,2,,103167833,4212,Active,,,7.2,IC50,Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay,Confirmatory,21507644.0,
994,602041,3,2,,103167833,4212,Active,,,8.2,IC50,Cytotoxicity against human HL60 cells after 24 hrs by MTT assay,Confirmatory,21507644.0,
995,602123,1,1,,92763439,4212,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
996,602141,1,1,,92763439,4212,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
997,602162,1,1,,92763439,4212,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
998,602163,1,1,,92763439,4212,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
999,602179,1,2,,92763439,4212,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
1000,602229,1,1,,92763439,4212,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1001,602233,1,1,,92763439,4212,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1002,602244,1,2,,92763439,4212,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
1003,602247,1,2,,92763439,4212,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1004,602248,1,2,,92763439,4212,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1005,602250,1,2,,92763439,4212,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
1006,602252,1,1,,92763439,4212,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1007,602252,1,1,,92763439,4212,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1008,602261,1,1,,92763439,4212,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
1009,602274,1,2,,92763439,4212,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
1010,602281,1,1,,92763439,4212,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1011,602281,1,1,,92763439,4212,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1012,602310,1,2,,92763439,4212,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1013,602313,1,1,,92763439,4212,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
1014,602332,1,1,,11111483,4212,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1015,602332,1,1,,90341083,4212,Inconclusive,168984549.0,,2.3281,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1016,602332,1,1,,92763439,4212,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1017,602342,2,1,,92763439,4212,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1018,602346,1,1,,92763439,4212,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1019,602396,1,2,,92763439,4212,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1020,602399,1,2,,92763439,4212,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
1021,602410,1,1,,92763439,4212,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
1022,602429,1,1,,92763439,4212,Active,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1023,602438,1,1,,92763439,4212,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1024,602440,1,1,,92763439,4212,Active,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1025,602449,1,2,,92763439,4212,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1026,613825,1,4,,103167833,4212,Unspecified,,,,,Ratio of IC50 for daunorubicin-resistant human HL60 cells to IC50 for human HL60 cells,Other,21780800.0,
1027,613826,1,4,,103167833,4212,Unspecified,,,,,Ratio of IC50 for homoharringtonine300-resistant human K562 cells to IC50 for human K562 cells,Other,21780800.0,
1028,613827,1,4,,103167833,4212,Unspecified,,,,,Ratio of IC50 for vinblastine100-resistant human CCRF-CEM cells to IC50 for human CCRF-CEM cells,Other,21780800.0,
1029,623870,1,1,,92763439,4212,Active,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1030,623870,1,1,,92763439,4212,Active,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1031,623877,1,1,,92763439,4212,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1032,623901,1,1,,92763439,4212,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1033,624030,1,2,,11111483,4212,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
1034,624031,1,2,,11111483,4212,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
1035,624032,1,2,,11111483,4212,Active,8393992.0,24660.0,0.3464,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
1036,624037,1,3,,92763439,4212,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1037,624038,1,3,,92763439,4212,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1038,624040,1,3,,92763439,4212,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1039,624044,1,2,,11111483,4212,Inconclusive,8393992.0,24660.0,0.4248,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
1040,624101,1,2,,85788828,4212,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1041,624125,1,4,,92763439,4212,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1042,624126,1,3,,92763439,4212,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1043,624127,1,2,,92763439,4212,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1044,624137,1,1,,85788828,4212,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
1045,624146,1,1,,90341083,4212,Active,71051501.0,2744.0,3.5481,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
1046,624147,1,1,,90341083,4212,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
1047,624148,1,2,,90341083,4212,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
1048,624149,1,1,,90341083,4212,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
1049,624156,1,1,,85788828,4212,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1050,624160,1,1,,11111483,4212,Active,,,6.7931,Potency,qHTS Fluorescence Polarization (FP) Assay for Inhibitors of MLL CXXC domain - DNA interaction: Fluorescein FP,Confirmatory,,
1051,624161,1,1,,11111483,4212,Active,,,12.08,Potency,qHTS Fluorescence Polarization (FP) Assay for Inhibitors of MLL CXXC domain - DNA interaction: Texas Red FP,Confirmatory,,
1052,624162,1,2,,11111483,4212,Active,,,7.3495,Potency,qHTS Fluorescence Polarization (FP) Assay for Inhibitors of MLL CXXC domain - DNA interaction: HTRF Assay,Confirmatory,,
1053,624168,1,1,,92763439,4212,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1054,624169,1,1,,92763439,4212,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1055,624170,1,1,,11111483,4212,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1056,624170,1,1,,92763439,4212,Inactive,71051501.0,2744.0,5.6234,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1057,624171,1,1,,92763439,4212,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1058,624172,1,1,,11111483,4212,Inactive,1724069.0,2740.0,7.0795,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1059,624172,1,1,,92763439,4212,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1060,624173,1,3,,11111483,4212,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1061,624173,1,3,,92763439,4212,Inconclusive,62359610.0,,39.8107,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1062,624178,1,1,,92763439,4212,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1063,624202,1,1,,92763439,4212,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1064,624204,1,2,,92763439,4212,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1065,624246,1,1,,92763439,4212,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1066,624260,1,1,,85788828,4212,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1067,624263,1,1,,92763439,4212,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1068,624263,1,1,,92763439,4212,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1069,624267,1,2,,92763439,4212,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1070,624267,1,2,,92763439,4212,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1071,624268,1,3,,92763439,4212,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1072,624287,1,1,,92763439,4212,Inactive,52000961.0,2778.0,,Potency,"qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1073,624288,1,1,,92763439,4212,Inconclusive,52000961.0,2778.0,22.3872,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1074,624291,1,1,,92763439,4212,Inactive,121312.0,1081.0,1.122,Potency,qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy,Confirmatory,,
1075,624296,1,1,,11111483,4212,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1076,624296,1,1,,92763439,4212,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1077,624297,1,1,,11111483,4212,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1078,624297,1,1,,92763439,4212,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1079,624300,1,1,,92763439,4212,Active,,,6.341,CC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  HeLa Cytotoxicity,Confirmatory,,
1080,624304,1,2,,92763439,4212,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1081,624330,1,2,,92763439,4212,Active,21361397.0,29127.0,14.46,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1082,624349,1,2,,92309061,4212,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1083,624351,1,1,,92763439,4212,Active,,,100.0,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP - Counter Screen Coupled Enzyme,Confirmatory,,
1084,624352,1,1,,92763439,4212,Active,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1085,624354,1,1,,92763439,4212,Active,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1086,624377,1,1,,92763439,4212,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1087,624414,1,1,,92763439,4212,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1088,624415,1,2,,92763439,4212,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1089,624416,1,1,,92763439,4212,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1090,624417,1,1,,92763439,4212,Inconclusive,1724069.0,2740.0,35.4813,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1091,624418,1,1,,92763439,4212,Inconclusive,,,4.4668,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1092,624455,1,1,,90341083,4212,Inconclusive,299681.0,1812.0,5.1735,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
1093,624463,1,1,,92763439,4212,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1094,624464,1,1,,92763439,4212,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1095,624465,1,1,,92763439,4212,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1096,624466,1,3,,92763439,4212,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1097,624467,1,1,,92763439,4212,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1098,624483,1,1,,92763439,4212,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1099,624606,1,9,,103167833,4212,Unspecified,136729.0,54658.0,,,Specific activity of expressed human recombinant UGT1A1,Other,10836148.0,
1100,624609,1,9,,103167833,4212,Unspecified,29840832.0,54578.0,,,Specific activity of expressed human recombinant UGT1A6,Other,10836148.0,
1101,624612,1,9,,103167833,4212,Unspecified,29839451.0,54600.0,,,Specific activity of expressed human recombinant UGT1A9,Other,10836148.0,
1102,624622,3,1,,103167833,4212,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
1103,624623,3,1,,103167833,4212,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells,Other,11602674.0,
1104,624626,1,9,,103167833,4212,Unspecified,238054374.0,5243.0,,,Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
1105,624628,1,9,,103167833,4212,Unspecified,238054374.0,5243.0,,,Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM,Other,11602674.0,
1106,624629,1,9,,103167833,4212,Unspecified,238054374.0,5243.0,,,Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay,Other,11602674.0,
1107,625144,5,5,,103167833,4212,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1108,625145,4,7,,103167833,4212,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1109,625146,5,5,,103167833,4212,Active,126397.0,100009114.0,1.7853,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1110,625147,4,7,,103167833,4212,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1111,625148,4,7,,103167833,4212,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1112,625149,4,7,,103167833,4212,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1113,625150,5,5,,103167833,4212,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1114,625151,4,7,,103167833,4212,Active,113118.0,1128.0,0.7487,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1115,625152,4,7,,103167833,4212,Active,113122.0,1129.0,0.21899999999999997,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1116,625153,4,7,,103167833,4212,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1117,625154,4,7,,103167833,4212,Active,23503039.0,1132.0,0.6441,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1118,625155,4,7,,103167833,4212,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1119,625156,1,9,,103167833,4212,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1120,625157,6,2,,103167833,4212,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1121,625158,3,4,,103167833,4212,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1122,625159,5,5,,103167833,4212,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1123,625160,1,9,,103167833,4212,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1124,625161,4,7,,103167833,4212,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1125,625162,4,7,,103167833,4212,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1126,625163,4,7,,103167833,4212,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1127,625164,1,6,,103167833,4212,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1128,625165,3,4,,103167833,4212,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1129,625166,3,4,,103167833,4212,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1130,625167,5,5,,103167833,4212,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1131,625168,4,7,,103167833,4212,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1132,625169,1,6,,103167833,4212,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1133,625170,3,4,,103167833,4212,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1134,625171,4,7,,103167833,4212,Active,7531135.0,3757.0,3.5849,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1135,625172,4,7,,103167833,4212,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1136,625173,5,5,,103167833,4212,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1137,625174,5,5,,103167833,4212,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1138,625175,5,5,,103167833,4212,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1139,625176,1,9,,103167833,4212,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1140,625177,5,5,,103167833,4212,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1141,625178,5,5,,103167833,4212,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1142,625179,1,9,,103167833,4212,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1143,625180,5,5,,103167833,4212,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1144,625181,5,5,,103167833,4212,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1145,625182,5,5,,103167833,4212,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1146,625183,5,5,,103167833,4212,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1147,625184,5,5,,103167833,4212,Active,2811086.0,1956.0,5.3859,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1148,625185,5,5,,103167833,4212,Active,125370.0,2534.0,1.2579,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1149,625186,5,5,,103167833,4212,Active,119533.0,2064.0,2.0352,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1150,625187,5,5,,103167833,4212,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1151,625188,1,9,,103167833,4212,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1152,625189,1,7,,103167833,4212,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1153,625190,4,5,,103167833,4212,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1154,625191,4,7,,103167833,4212,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1155,625192,4,7,,103167833,4212,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1156,625193,5,5,,103167833,4212,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1157,625194,4,7,,103167833,4212,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1158,625195,4,7,,103167833,4212,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1159,625196,5,6,,103167833,4212,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1160,625197,3,4,,103167833,4212,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1161,625198,4,7,,103167833,4212,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1162,625199,4,7,,103167833,4212,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1163,625200,4,7,,103167833,4212,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1164,625201,4,7,,103167833,4212,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1165,625202,4,7,,103167833,4212,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1166,625203,4,7,,103167833,4212,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1167,625204,4,7,,103167833,4212,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1168,625205,4,7,,103167833,4212,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1169,625206,4,7,,103167833,4212,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1170,625207,4,7,,103167833,4212,Active,128616.0,6530.0,4.9898,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1171,625208,5,5,,103167833,4212,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1172,625209,4,7,,103167833,4212,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1173,625210,3,4,,103167833,4212,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1174,625211,1,6,,103167833,4212,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1175,625212,3,4,,103167833,4212,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1176,625213,4,7,,103167833,4212,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1177,625214,1,9,,103167833,4212,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1178,625215,3,4,,103167833,4212,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1179,625216,3,4,,103167833,4212,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1180,625217,4,7,,103167833,4212,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1181,625218,4,7,,103167833,4212,Active,112816.0,3358.0,3.5619,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1182,625219,3,4,,103167833,4212,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1183,625220,4,7,,103167833,4212,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1184,625221,4,7,,103167833,4212,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1185,625222,4,7,,103167833,4212,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1186,625223,4,7,,103167833,4212,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1187,625224,3,4,,103167833,4212,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1188,625225,3,4,,103167833,4212,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1189,625226,4,7,,103167833,4212,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1190,625227,4,7,,103167833,4212,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1191,625228,4,7,,103167833,4212,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1192,625229,5,5,,103167833,4212,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1193,625230,1,6,,103167833,4212,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1194,625231,4,7,,103167833,4212,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1195,625232,1,9,,103167833,4212,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1196,625233,4,7,,103167833,4212,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1197,625234,3,4,,103167833,4212,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1198,625235,4,7,,103167833,4212,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1199,625236,5,5,,103167833,4212,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1200,625237,4,7,,103167833,4212,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1201,625238,4,7,,103167833,4212,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1202,625239,4,7,,103167833,4212,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1203,625240,1,9,,103167833,4212,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1204,625241,4,7,,103167833,4212,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1205,625242,4,7,,103167833,4212,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1206,625243,5,5,,103167833,4212,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1207,625244,5,5,,103167833,4212,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1208,625245,5,5,,103167833,4212,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1209,625246,1,9,,103167833,4212,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1210,625247,5,5,,103167833,4212,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1211,625248,5,5,,103167833,4212,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1212,625249,5,5,,103167833,4212,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1213,625250,5,5,,103167833,4212,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1214,625251,5,5,,103167833,4212,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1215,625252,4,7,,103167833,4212,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1216,625253,4,7,,103167833,4212,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1217,625254,4,7,,103167833,4212,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1218,625255,4,7,,103167833,4212,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1219,625256,4,7,,103167833,4212,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1220,625257,4,7,,103167833,4212,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1221,625258,4,7,,103167833,4212,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1222,625259,4,7,,103167833,4212,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1223,625260,3,4,,103167833,4212,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1224,625261,3,4,,103167833,4212,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1225,625262,3,4,,103167833,4212,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1226,625263,4,7,,103167833,4212,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1227,625264,3,4,,103167833,4212,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1228,625265,1,6,,103167833,4212,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1229,625266,3,4,,103167833,4212,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1230,625267,3,4,,103167833,4212,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1231,625268,4,2,,103167833,4212,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1232,625268,4,2,,103167833,4212,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1233,625268,4,2,,103167833,4212,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1234,625268,4,2,,103167833,4212,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1235,625269,4,7,,103167833,4212,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1236,625270,4,7,,103167833,4212,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1237,625271,5,5,,103167833,4212,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1238,625272,3,4,,103167833,4212,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1239,625273,4,6,,103167833,4212,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1240,625274,1,6,,103167833,4212,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1241,625275,3,4,,103167833,4212,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1242,625279,1,3,,103167833,4212,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
1243,625280,1,3,,103167833,4212,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
1244,625281,1,3,,103167833,4212,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
1245,625282,1,3,,103167833,4212,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
1246,625283,1,3,,103167833,4212,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
1247,625284,1,3,,103167833,4212,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
1248,625285,1,3,,103167833,4212,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
1249,625286,1,3,,103167833,4212,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
1250,625287,1,3,,103167833,4212,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
1251,625288,1,3,,103167833,4212,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
1252,625289,1,3,,103167833,4212,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
1253,625290,1,3,,103167833,4212,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
1254,625291,1,3,,103167833,4212,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
1255,625292,1,3,,103167833,4212,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
1256,627483,1,5,,103167833,4212,Unspecified,,,,,Inhibition of ATP-dependent ABCG2 pump assessed as ratio of compound IC50 for HEK/ABCG2-482-R2 cells to IC50 for HEK293/pcDNA3.1 cells after 72 hrs by MTT assay,Other,21920748.0,
1257,635081,3,2,,103167833,4212,Active,,,0.29,IC50,Cytotoxicity against human PC3 cells after 48 hrs by SRB assay,Confirmatory,22100139.0,
1258,647959,1,3,,103167833,4212,Unspecified,,,,,Inhibition of human TERT expression in H1299 cells at 1 uM after 24 hrs by secreted alkaline phosphatase reporter gene assay relative to control,Other,22357112.0,
1259,647960,1,3,,103167833,4212,Unspecified,,,,,Inhibition of human TERT expression in H1299 cells at 10 uM after 24 hrs by secreted alkaline phosphatase reporter gene assay relative to control,Other,22357112.0,
1260,647961,1,3,,103167833,4212,Unspecified,,,,,Inhibition of human TERT expression in H1299 cells at 100 uM after 24 hrs by secreted alkaline phosphatase reporter gene assay relative to control,Other,22357112.0,
1261,647962,1,4,,103167833,4212,Unspecified,,,,,Cytotoxicity against human H1299 cells assessed as cell growth at 1 uM after 48 hrs by MTT assay,Other,22357112.0,
1262,647963,1,4,,103167833,4212,Unspecified,,,,,Cytotoxicity against human H1299 cells assessed as cell growth at 10 uM after 48 hrs by MTT assay,Other,22357112.0,
1263,647964,1,4,,103167833,4212,Unspecified,,,,,Cytotoxicity against human H1299 cells assessed as cell growth at 100 uM after 48 hrs by MTT assay,Other,22357112.0,
1264,651548,1,1,,85788828,4212,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1265,651550,1,1,,92763439,4212,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1266,651560,1,1,,92763439,4212,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1267,651572,1,2,,92763439,4212,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1268,651582,1,1,,92763439,4212,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1269,651602,1,1,,92763439,4212,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1270,651602,1,1,,92763439,4212,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1271,651602,1,1,,92763439,4212,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1272,651610,2,1,,92763439,4212,Active,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1273,651635,1,3,,90341083,4212,Inconclusive,171543895.0,6311.0,10.0,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1274,651635,1,3,,92763439,4212,Active,171543895.0,6311.0,2.9935,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1275,651636,1,1,,92763439,4212,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1276,651640,1,1,,92763439,4212,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1277,651644,1,1,,92763439,4212,Inconclusive,28872817.0,155807.0,11.2202,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1278,651647,1,1,,92763439,4212,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1279,651658,1,1,,92763439,4212,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1280,651661,2,1,,92763439,4212,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1281,651687,1,1,,92763439,4212,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1282,651699,1,1,,92763439,4212,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1283,651699,1,1,,92763439,4212,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1284,651702,1,2,,92763439,4212,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1285,651704,2,1,,92763439,4212,Active,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1286,651710,1,1,,92763439,4212,Active,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1287,651711,2,1,,92763439,4212,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1288,651718,1,2,,92763439,4212,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1289,651719,1,2,,92763439,4212,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
1290,651723,1,1,,92763439,4212,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1291,651724,1,1,,92763439,4212,Active,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1292,651725,1,1,,92763439,4212,Active,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1293,651768,1,2,,92763439,4212,Active,3719421.0,7486.0,8.9125,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1294,651800,1,1,,92763439,4212,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1295,651819,1,1,,92763439,4212,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1296,651820,1,1,,92763439,4212,Inconclusive,,,1.4125,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1297,651821,2,4,,92763439,4212,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1298,651957,1,1,,92763439,4212,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1299,651958,1,1,,92763439,4212,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1300,651965,1,1,,92763439,4212,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1301,651999,1,1,,92763439,4212,Active,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1302,652010,1,1,,92763439,4212,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1303,652017,1,1,,92763439,4212,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1304,652025,1,1,,92763439,4212,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1305,652039,1,1,,92763439,4212,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
1306,652048,1,2,,92763439,4212,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1307,652051,1,1,,92763439,4212,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1308,652054,1,1,,92763439,4212,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1309,652067,1,4,,92763439,4212,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1310,652104,1,1,,92763439,4212,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1311,652105,1,1,,92763439,4212,Inconclusive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1312,652106,1,1,,90341083,4212,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1313,652106,1,1,,92763439,4212,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1314,652115,1,1,,92763439,4212,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
1315,652116,1,1,,92763439,4212,Active,109637798.0,5893.0,0.244,AC50_uM,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1316,652126,1,3,,92763439,4212,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1317,652128,1,1,,92763439,4212,Inactive,,,,AC50_uM,RAD52: DNA binders Measured in Biochemical System Using Plate Reader - 7018-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1318,652142,1,1,,92763439,4212,Inactive,186910300.0,29127.0,,,Biochemical MgcRacGAP assay detecting GTPase activation of the target GTPase Rac1 through the measurement of inorganic phosphate.,Other,,
1319,652154,1,1,,92763439,4212,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1320,652154,1,1,,124360065,4212,Inconclusive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1321,652162,2,1,,92763439,4212,Active,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1322,652163,1,1,,92763439,4212,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1323,652197,1,1,,92763439,4212,Active,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1324,652257,1,1,,92763439,4212,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1325,678804,1,8,,103167833,4212,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: ATP hydrolysis in membrane vesicle from BCRP-expressing Sf9 cells,Other,11437380.0,
1326,678963,1,8,,103167833,4212,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: uptake in BCRP-expressing oocyte cells,Other,14645676.0,
1327,678965,1,8,,103167833,4212,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: drug resistance in BCRP-expressing PA317 cells,Other,14566825.0,
1328,679126,1,8,,103167833,4212,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells,Other,14706813.0,
1329,679172,1,8,,103167833,4212,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: drug resistance in BCRP-expressing LLC-PK1 cells,Other,12920197.0,
1330,679173,1,8,,103167833,4212,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: drug resistance in BCRP-expressing K562 cells,Other,12533678.0,
1331,680980,1,8,,103167833,4212,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: intracellular accumulation in S1 and S1-M1-80 cells,Other,10806112.0,
1332,680981,1,8,,103167833,4212,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: intracellular accumulation in MCF-7 and MCF-7 AdVp3000 cells,Other,10806112.0,
1333,680987,1,8,,103167833,4212,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: inhibition of MTX update by Mitoxantrone at a concentration of 50uM in membrane vesicles from BCRP-expressing MCF7 cells,Other,14500392.0,
1334,681062,1,8,,103167833,4212,Unspecified,1170902.0,24646.0,,,TP_TRANSPORTER: Northern blot from primary hepatocytes,Other,8937457.0,
1335,681063,1,8,,103167833,4212,Unspecified,1170902.0,24646.0,,,TP_TRANSPORTER: Northern blot in vivo Wistar rat,Other,8937457.0,
1336,681085,1,8,,103167833,4212,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: transport in etoposide-selected MCF7 cells,Other,16434618.0,
1337,681121,1,8,,103167833,4212,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing MDCKII cells,Other,11602674.0,
1338,681130,1,8,,103167833,4212,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells,Other,11602674.0,
1339,681132,1,8,,103167833,4212,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells,Other,11602674.0,
1340,681446,1,8,,103167833,4212,Unspecified,68052328.0,26357.0,,,"TP_TRANSPORTER: cell accumulation in MEF3.8, M32 and T6400 cells",Other,10485464.0,
1341,681447,1,8,,103167833,4212,Unspecified,68052328.0,26357.0,,,TP_TRANSPORTER: cell accumulation in KOT52 and D320 cells,Other,10485464.0,
1342,681494,1,7,,103167833,4212,Unspecified,81911503.0,,,,TP_TRANSPORTER: Northern blot in vivo Wistar rat,Other,8937457.0,
1343,681508,1,8,,103167833,4212,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: efflux in MCF7/VP and MCF cells,Other,11454692.0,
1344,681514,2,6,,103167833,4212,Unspecified,296439301.0,4363.0,0.0015,IC50,TP_TRANSPORTER: cell accumulation in MCF7/MRP1-M6 cells,Confirmatory,16434618.0,
1345,681515,2,6,,103167833,4212,Unspecified,296439301.0,4363.0,0.0015,IC50,TP_TRANSPORTER: cell accumulation in MCF7/MRP1-M24 cells,Confirmatory,16434618.0,
1346,681516,2,6,,103167833,4212,Unspecified,296439301.0,4363.0,0.0019,IC50,TP_TRANSPORTER: cell accumulation in MCF7/MRP1-10 cells,Confirmatory,16434618.0,
1347,681522,1,8,,103167833,4212,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: ATP- and GSH-dependent transport in MCF7/MRP1-10 cells,Other,16434618.0,
1348,681563,1,8,,103167833,4212,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: Cytotoxicity in MT-4 and MT-4/DOX500 cells,Other,12488537.0,
1349,681572,1,8,,103167833,4212,Unspecified,68052328.0,26357.0,,,TP_TRANSPORTER: drug resistance in BCRP-expressing MEF3.8 cells,Other,12649196.0,
1350,682127,1,8,,103167833,4212,Unspecified,126927.0,18669.0,,,TP_TRANSPORTER: Northern blot in vivo NMRI mouse,Other,8937457.0,
1351,683854,2,2,,103167833,4212,Inconclusive,,,,IC50,Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay,Confirmatory,22944121.0,
1352,683855,2,3,,103167833,4212,Inconclusive,,,,IC50,Antiproliferative activity against human LoVo/DX cells after 72 hrs by SRB assay,Confirmatory,22944121.0,
1353,683857,2,3,,103167833,4212,Inconclusive,,,,IC50,Antiproliferative activity against human MESSA cells after 72 hrs by SRB assay,Confirmatory,22944121.0,
1354,683858,2,3,,103167833,4212,Inconclusive,,,,IC50,Antiproliferative activity against human MESSA/DX5 cells after 72 hrs by SRB assay,Confirmatory,22944121.0,
1355,683860,2,2,,103167833,4212,Active,,,0.0025,IC50,Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay,Confirmatory,22944121.0,
1356,683861,2,3,,103167833,4212,Active,,,0.561,IC50,Antiproliferative activity against human HL60/MX2 cells after 72 hrs by SRB assay,Confirmatory,22944121.0,
1357,683862,1,2,,103167833,4212,Unspecified,,,,,"Resistance index, ratio of IC50 for human HL60/MX2 cells to IC50 for human HL60 cells",Other,22944121.0,
1358,686940,1,1,,92763439,4212,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1359,686947,2,2,,162108252,4212,Active,4885661.0,7525.0,34.4993,Potency,qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen,Confirmatory,23787099.0,
1360,686950,1,1,,162108252,4212,Inactive,,,,Potency,qHTS for small molecule inhibitors of Yes1 kinase: Counter Assay,Other,,
1361,686964,1,1,,92763439,4212,Active,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1362,686970,1,2,,92763439,4212,Inconclusive,49168486.0,3417.0,20.5962,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1363,686971,1,2,,92763439,4212,Active,,,23.1093,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1364,686977,2,1,,49698959,4212,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
1365,686978,1,1,,92763439,4212,Active,79154014.0,55775.0,0.0326,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1366,686979,1,1,,92763439,4212,Active,79154014.0,55775.0,0.1836,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1367,686996,1,1,,92763439,4212,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1368,687014,1,1,,92763439,4212,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1369,687016,1,1,,92763439,4212,Active,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1370,687157,2,2,,103167833,4212,Active,,,0.016,IC50,Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay,Confirmatory,22582991.0,
1371,687158,4,1,,103167833,4212,Active,,,0.51,IC50,Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay,Confirmatory,22582991.0,
1372,687159,4,1,,103167833,4212,Active,,,0.036000000000000004,IC50,Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay,Confirmatory,22582991.0,
1373,687160,1,2,,103167833,4212,Unspecified,,,,,Ratio of IC50 for human HL60/MX2 cells to IC50 for human HL60 cells,Other,22582991.0,
1374,687161,1,2,,103167833,4212,Unspecified,,,,,Ratio of IC50 for human HL60/ADR cells to IC50 for human HL60 cells,Other,22582991.0,
1375,687162,1,2,,103167833,4212,Unspecified,,,,,Ratio of IC50 for daunorubicin-resistant human HL60 cells to IC50 for human HL60 cells,Other,22582991.0,
1376,687163,1,2,,103167833,4212,Unspecified,,,,,Ratio of IC50 for doxorubicin-resistant human HL60 cells to IC50 for human HL60 cells,Other,22582991.0,
1377,687164,1,2,,103167833,4212,Unspecified,,,,,Ratio of IC50 for doxorubicin-resistant human K562 cells to IC50 for human K562 cells,Other,22582991.0,
1378,687165,1,2,,103167833,4212,Unspecified,,,,,Ratio of IC50 for human K562/HHT300 cells to IC50 for human K562 cells,Other,22582991.0,
1379,687166,1,2,,103167833,4212,Unspecified,,,,,Ratio of IC50 for human CCRF-CEM/C2 cells IC50 for human CCRF-CEM cells,Other,22582991.0,
1380,687167,1,2,,103167833,4212,Unspecified,,,,,Ratio of IC50 for human CCRF-CEM/VM-1-5 cells IC50 for human CCRF-CEM cells,Other,22582991.0,
1381,687168,1,2,,103167833,4212,Unspecified,,,,,Ratio of IC50 for human CCRF-CEM/VLB100 cells IC50 for human CCRF-CEM cells,Other,22582991.0,
1382,699539,1,7,,103167833,4212,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
1383,699540,1,7,,103167833,4212,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1384,699541,1,7,,103167833,4212,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1385,720494,1,1,,92763439,4212,Active,,,0.355,AC50_uM,Alphascreen Interference Assay Measured in Biochemical System Using Plate Reader - 2160-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1386,720495,1,1,,92763439,4212,Active,156104889.0,4300.0,0.374,AC50_uM,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1387,720496,1,1,,92763439,4212,Active,154350220.0,11201.0,2.9935,Potency,qHTS for Inhibitors of Polymerase Iota: Confirmatory Assay for Cherry-picked Compounds,Confirmatory,,
1388,720497,1,1,,92763439,4212,Active,3719421.0,7486.0,0.9614,Potency,qHTS for Inhibitors of WRN Helicase: Confirmatory Assay for Cherry-picked Compounds.,Confirmatory,,
1389,720498,1,2,,92763439,4212,Active,4758356.0,2237.0,1.3459,Potency,qHTS Assay for the Inhibitors of FEN1: Confirmatory Assay for Cherry-picked Compounds,Confirmatory,,
1390,720499,1,1,,92763439,4212,Active,,,0.4294,Potency,qHTS for Inhibitors of WRN Helicase: Thiazole Orange DNA Binding Counterscreen,Confirmatory,,
1391,720501,1,1,,92763439,4212,Active,7705344.0,51426.0,2.3778,Potency,qHTS for Inhibitors of Polymerase Kappa: Confirmatory Assay for Cherry-picked Compounds,Confirmatory,23056190.0,
1392,720502,1,1,,92763439,4212,Active,5729982.0,5429.0,19.0115,Potency,qHTS for Inhibitors of Polymerase Eta: Confirmatory Assay for Cherry-picked Compounds,Confirmatory,,
1393,720503,1,1,,92763439,4212,Active,4557365.0,641.0,1.358,Potency,qHTS for Inhibitors of WRN Helicase: BLM Helicase Counterscreen for WRN Inhibitors,Confirmatory,,
1394,720504,1,1,,92763439,4212,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1395,720508,1,1,,92763439,4212,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1396,720509,1,1,,92763439,4212,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1397,720511,1,1,,92763439,4212,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1398,720512,2,1,,92763439,4212,Inactive,126698238.0,4914074.0,,AC50_uM,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1399,720530,1,1,,92763439,4212,Active,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1400,720531,1,1,,92763439,4212,Active,21595776.0,8932.0,,,TRFRET-based biochemical high throughput confirmation assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1401,720538,1,2,,90341083,4212,Active,220983390.0,410.0,23.9341,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
1402,720542,1,2,,92763439,4212,Active,23496270.0,810891.0,10.0,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1403,720543,1,1,,92763439,4212,Active,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1404,720551,1,2,,92763439,4212,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1405,720559,1,2,,90341083,4212,Inactive,112927.0,351.0,23.1093,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
1406,720572,1,2,,90341083,4212,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
1407,720573,1,2,,90341083,4212,Inactive,3063388.0,5071.0,23.1093,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
1408,720579,2,1,,92763439,4212,Inconclusive,222762.0,3707576.0,0.3162,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1409,720580,1,1,,92763439,4212,Active,222762.0,3707576.0,10.0,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1410,720582,1,1,,92763439,4212,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1411,720596,1,1,,92763439,4212,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1412,720641,1,2,,92309061,4212,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
1413,720648,1,1,,92763439,4212,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1414,720650,1,1,,92763439,4212,Active,,,23.89,AC50_uM,C. difficile toxins: Counterscreen in absence of substrate UDPG Measured in Biochemical System Using Plate Reader - 7074-02_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1415,720654,1,1,,92763439,4212,Inactive,38027923.0,10987.0,,,Single Concentration Validation of Csn-Mediated Deneddylation of Cullin-Ring Ligase Using a Fluorescence Polarization Assay,Other,,
1416,720655,1,1,,92763439,4212,Active,11342666.0,4313.0,,,Single concentration validation of Csn-Mediated Deneddylation of Cullin-Ring Ligase Hits Using a MMP-2 Fluorescence Assay,Other,,
1417,720656,1,1,,92763439,4212,Inactive,296479639.0,280685.0,,,Single concentration validation of Csn-Mediated Deneddylation of Cullin-Ring Ligase Using a Thrombin Fluorescence Polarization Assay,Other,,
1418,720658,1,1,,92763439,4212,Active,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput confirmation assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1419,720700,1,4,,92763439,4212,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1420,720702,1,1,,92763439,4212,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1421,720704,1,4,,92763439,4212,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1422,720707,1,2,,92763439,4212,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1423,720708,1,2,,92763439,4212,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
1424,720709,1,2,,92763439,4212,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1425,720711,1,2,,92763439,4212,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
1426,720717,1,3,,92309061,4212,Active,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1427,721742,1,2,,103167833,4212,Unspecified,,,,,Ratio of Cmax unbound to IC50 for human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells,Other,23241029.0,
1428,721743,1,2,,103167833,4212,Unspecified,,,,,Ratio of Cmax unbound to IC50 for human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells,Other,23241029.0,
1429,721745,1,2,,103167833,4212,Unspecified,,,,,Ratio of Cmax unbound to IC50 for human MATE1-mediated ASP+ uptake expressed in HEK293 cells,Other,23241029.0,
1430,721746,2,5,,103167833,4212,Active,74731723.0,55244.0,0.19,IC50,Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis,Confirmatory,23241029.0,
1431,721747,2,5,,103167833,4212,Active,74731723.0,55244.0,0.4,IC50,Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis,Confirmatory,23241029.0,
1432,721748,2,5,,103167833,4212,Active,74727585.0,146802.0,0.53,IC50,Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
1433,721749,2,5,,103167833,4212,Unspecified,24212063.0,6581.0,60.5,IC50,Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay,Confirmatory,23241029.0,
1434,721750,2,5,,103167833,4212,Active,313104181.0,6580.0,43.9,IC50,Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay,Confirmatory,23241029.0,
1435,721751,2,5,,103167833,4212,Unspecified,313104182.0,6582.0,73.3,IC50,Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay,Confirmatory,23241029.0,
1436,721752,2,5,,103167833,4212,Active,74727585.0,146802.0,0.83,IC50,Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
1437,721754,2,5,,103167833,4212,Active,74731723.0,55244.0,0.53,IC50,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
1438,729375,1,3,,103167833,4212,Inactive,,,,,Effect on total PIM1 level in human MV411 cells at 10 to 100 nM after 12 hrs by Western blotting analysis,Other,23442188.0,
1439,729376,1,6,,103167833,4212,Active,83305339.0,5292.0,,,Inhibition of PIM1-mediated BAD phosphorylation in human K562 cells at 0.1 to 30 uM after 12 hrs by Western blotting analysis,Other,23442188.0,
1440,729377,1,3,,103167833,4212,Inactive,,,,,Effect on total BAD level in human MV411 cells at 10 to 100 nM after 12 hrs by Western blotting analysis,Other,23442188.0,
1441,729378,1,6,,103167833,4212,Active,83305339.0,5292.0,,,Inhibition of PIM1-mediated BAD phosphorylation in human MV411 cells at 100 nM after 12 hrs by Western blotting analysis,Other,23442188.0,
1442,729379,1,6,,103167833,4212,Unspecified,83305339.0,5292.0,,,Inhibition of PIM1-mediated BAD phosphorylation in human MV411 cells after 12 hrs by Western blotting analysis,Other,23442188.0,
1443,729380,1,6,,103167833,4212,Unspecified,83305339.0,5292.0,,,Inhibition of PIM1-mediated BAD phosphorylation in human K562 cells after 12 hrs by Western blotting analysis,Other,23442188.0,
1444,729381,1,2,,103167833,4212,Active,,,0.66,IC50,Inhibition of human recombinant casein kinase 2 using [gamma-32P] ATP,Confirmatory,23442188.0,
1445,729382,2,5,,103167833,4212,Active,547759.0,695.0,1.0,IC50,Inhibition of BTK (unknown origin),Confirmatory,23442188.0,
1446,729384,1,6,,103167833,4212,Unspecified,547759.0,695.0,,,Inhibition of BTK (unknown origin) using [gamma33P]ATP assessed as residual activity at 1 uM after 120 mins by radiometric assay,Other,23442188.0,
1447,729385,1,6,,103167833,4212,Unspecified,60391226.0,207.0,,,Inhibition of AKT1 (unknown origin) using [gamma33P]ATP assessed as residual activity at 1 uM after 120 mins by radiometric assay,Other,23442188.0,
1448,729386,1,6,,103167833,4212,Unspecified,6685284.0,11200.0,,,Inhibition of CHK2 (unknown origin) using [gamma33P]ATP assessed as residual activity at 1 uM after 120 mins by radiometric assay,Other,23442188.0,
1449,729387,1,6,,103167833,4212,Unspecified,83305339.0,5292.0,,,Inhibition of PIM1 (unknown origin) using [gamma33P]ATP assessed as residual activity at 1 uM after 120 mins by radiometric assayATP,Other,23442188.0,
1450,729388,1,6,,103167833,4212,Unspecified,125266.0,1459.0,,,Inhibition of CK2alpha2 (unknown origin) using [gamma33P]ATP assessed as residual activity at 1 uM after 120 mins by radiometric assay,Other,23442188.0,
1451,729389,1,2,,103167833,4212,Active,,,0.8,IC50,Inhibition of Mycobacterium tuberculosis protein kinase B,Confirmatory,23442188.0,
1452,733186,1,4,,103167833,4212,Active,,,,,Binding affinity to calf thymus DNA up to 5 mM,Other,23395656.0,
1453,733189,1,3,,103167833,4212,Active,,,0.76,EC50,Antiproliferative activity against human RKOp27IND cells after 48 hrs,Confirmatory,23395656.0,
1454,733190,1,3,,103167833,4212,Active,,,0.09,EC50,Antiproliferative activity against human RKOp27 cells after 48 hrs,Confirmatory,23395656.0,
1455,733194,1,2,,103167833,4212,Active,,,0.12,EC50,Antiproliferative activity against human NCI-H460 cells after 48 hrs,Confirmatory,23395656.0,
1456,733196,1,2,,103167833,4212,Active,,,0.32,EC50,Antiproliferative activity against human SF268 cells after 48 hrs,Confirmatory,23395656.0,
1457,733197,1,3,,103167833,4212,Active,,,0.12,EC50,Antiproliferative activity against human SKOV3 cells after 48 hrs,Confirmatory,23395656.0,
1458,733200,1,3,,103167833,4212,Active,,,0.36,EC50,Antiproliferative activity against human KB/HeLa cells after 48 hrs,Confirmatory,23395656.0,
1459,743126,1,1,,92763439,4212,Active,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1460,743205,1,1,,90341083,4212,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
1461,743205,1,1,,90341083,4212,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
1462,743206,1,1,,90341083,4212,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
1463,743206,1,1,,90341083,4212,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
1464,743207,1,1,,90341083,4212,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
1465,743207,1,1,,90341083,4212,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
1466,743238,1,1,,92763439,4212,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
1467,743244,1,1,,90341083,4212,Active,,,1.4125,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1468,743247,1,2,,92763439,4212,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1469,743255,1,1,,92763439,4212,Inconclusive,118600387.0,7398.0,14.1254,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
1470,743266,1,2,,92763439,4212,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
1471,743269,1,1,,92763439,4212,Active,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1472,743269,1,1,,92763439,4212,Active,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1473,743279,1,2,,92763439,4212,Active,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
1474,743280,1,1,,92763439,4212,Active,119580345.0,50487.0,,,QFRET-based biochemical high throughput confirmation assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1475,743282,1,1,,92763439,4212,Inactive,,,,,Counterscreen for inhibitors of the HGIII-SPLA2: QFRET-based biochemical high throughput screening assay to identify inhibitors that optically interfere with 535nm fluorescence,Screening,,
1476,743344,1,1,,162108252,4212,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
1477,743345,1,1,,162108252,4212,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
1478,743346,1,1,,162108252,4212,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
1479,743347,1,1,,162108252,4212,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
1480,743364,1,2,,162108252,4212,Inactive,,,,Potency,qHTS profiling of inhibitors of Plasmodium falciparum (3D7) proliferation (acoustic dispense),Confirmatory,,
1481,743365,1,2,,162108252,4212,Inactive,,,,Potency,qHTS profiling of inhibitors of Plasmodium falciparum (DD2) proliferation (acoustic dispense),Confirmatory,,
1482,743366,1,2,,162108252,4212,Inactive,,,,Potency,qHTS profiling of inhibitors of Plasmodium falciparum (HB3) proliferation (acoustic dispense),Confirmatory,,
1483,743397,1,1,,92763439,4212,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1484,743398,1,1,,92763439,4212,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
1485,743445,1,1,,92763439,4212,Active,109633019.0,7468.0,,,"Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2",Screening,,
1486,743455,1,1,,92763439,4212,Inactive,,,121.794,IC50,Counterscreen for inhibitors of the HGIII-SPLA2: QFRET-based biochemical high throughput dose response assay to identify inhibitors that optically interfere with 535nm fluorescence,Confirmatory,,
1487,743457,1,1,,92763439,4212,Inactive,119580345.0,50487.0,121.794,IC50,QFRET-based biochemical high throughput dose response assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Confirmatory,,
1488,771325,1,1,,103167833,4212,Active,,,0.03,EC50,Cytotoxicity against human NCI-H460 cells after 48 hrs by resazurin dye assay,Confirmatory,23988351.0,
1489,771326,1,1,,103167833,4212,Inconclusive,,,,EC50,Cytotoxicity against human SKOV3 cells after 48 hrs by resazurin dye assay,Confirmatory,23988351.0,
1490,771327,1,2,,103167833,4212,Active,,,0.42,EC50,Cytotoxicity against human KB/HeLa cells after 48 hrs by resazurin dye assay,Confirmatory,23988351.0,
1491,772006,1,3,,103167833,4212,Unspecified,,,,,Growth inhibition of human QSG7701 cells at 10 uM after 48 hrs by MTT assay relative to control,Other,,
1492,772008,1,3,,103167833,4212,Unspecified,,,,,Growth inhibition of human HepG2 cells at 10 uM after 48 hrs by MTT assay relative to control,Other,,
1493,772009,1,3,,103167833,4212,Unspecified,,,,,Growth inhibition of human HCT116 cells at 10 uM after 48 hrs by MTT assay relative to control,Other,,
1494,772010,1,3,,103167833,4212,Unspecified,,,,,Growth inhibition of human K562 cells at 10 uM after 48 hrs by MTT assay relative to control,Other,,
1495,937218,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020819,Other,,
1496,937219,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020819,Other,,
1497,937220,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020819,Other,,
1498,937221,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020819,Other,,
1499,937222,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020819,Other,,
1500,937223,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020819,Other,,
1501,937224,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020819,Other,,
1502,937225,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020819,Other,,
1503,937226,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020819,Other,,
1504,937227,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020819,Other,,
1505,937228,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020819",Other,,
1506,937229,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020819,Other,,
1507,937230,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020819,Other,,
1508,937231,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020819,Other,,
1509,937232,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020819,Other,,
1510,937233,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020819,Other,,
1511,937234,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020819,Other,,
1512,937235,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020819,Other,,
1513,937236,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020819,Other,,
1514,938959,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020819,Other,,
1515,938960,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020819,Other,,
1516,938961,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020819,Other,,
1517,938962,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020819",Other,,
1518,938963,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020819,Other,,
1519,938964,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020819,Other,,
1520,938965,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020819,Other,,
1521,938966,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020819,Other,,
1522,938967,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020819,Other,,
1523,938968,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020819,Other,,
1524,938969,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020819,Other,,
1525,938970,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020819,Other,,
1526,938971,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020819,Other,,
1527,938972,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020819,Other,,
1528,938973,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020819,Other,,
1529,939602,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020819,Other,,
1530,939603,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020819,Other,,
1531,939604,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020819,Other,,
1532,939605,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020819,Other,,
1533,950122,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020819,Other,,
1534,950123,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020819,Other,,
1535,950124,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020819,Other,,
1536,950125,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020819,Other,,
1537,950126,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020819,Other,,
1538,950127,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020819,Other,,
1539,950128,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020819,Other,,
1540,950129,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020819,Other,,
1541,950130,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020819,Other,,
1542,950131,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020819,Other,,
1543,950132,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020819,Other,,
1544,952152,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020819,Other,,
1545,952153,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020819,Other,,
1546,952154,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020819,Other,,
1547,952155,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020819,Other,,
1548,952156,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020819,Other,,
1549,952157,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020819,Other,,
1550,952158,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020819,Other,,
1551,952159,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020819,Other,,
1552,972144,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020819,Other,,
1553,972145,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020819,Other,,
1554,972146,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020819,Other,,
1555,972147,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020819,Other,,
1556,972148,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020819,Other,,
1557,972149,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020819,Other,,
1558,972150,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020819,Other,,
1559,972151,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020819,Other,,
1560,972152,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020819,Other,,
1561,972153,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020819,Other,,
1562,972154,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020819,Other,,
1563,972155,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020819,Other,,
1564,972156,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020819,Other,,
1565,972157,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020819,Other,,
1566,972158,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020819,Other,,
1567,972159,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020819,Other,,
1568,972160,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020819,Other,,
1569,972161,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020819,Other,,
1570,972162,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020819,Other,,
1571,977608,3,1,,46394146,4212,Active,112490636.0,,0.8,IC50,Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB,Other,16674948.0,
1572,978767,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020819,Other,,
1573,978768,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020819",Other,,
1574,978769,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020819",Other,,
1575,978770,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020819",Other,,
1576,978771,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S020819",Other,,
1577,978772,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S020819",Other,,
1578,978773,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S020819",Other,,
1579,978774,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020819",Other,,
1580,978775,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020819",Other,,
1581,978776,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020819",Other,,
1582,978777,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020819",Other,,
1583,978778,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020819",Other,,
1584,978779,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020819",Other,,
1585,978780,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S020819",Other,,
1586,978781,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S020819",Other,,
1587,978782,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S020819",Other,,
1588,978783,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S020819",Other,,
1589,978784,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020819",Other,,
1590,978785,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S020819",Other,,
1591,978786,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S020819",Other,,
1592,978787,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020819",Other,,
1593,978788,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020819,Other,,
1594,978789,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020819",Other,,
1595,978790,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020819",Other,,
1596,978791,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S020819",Other,,
1597,978792,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020819",Other,,
1598,978793,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S020819",Other,,
1599,978794,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S020819",Other,,
1600,978795,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S020819",Other,,
1601,978796,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S020819",Other,,
1602,978797,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S020819",Other,,
1603,979263,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020819,Other,,
1604,979264,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020819",Other,,
1605,979265,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020819",Other,,
1606,979266,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020819",Other,,
1607,979267,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020819",Other,,
1608,979268,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020819",Other,,
1609,979269,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020819",Other,,
1610,979270,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020819",Other,,
1611,979271,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S020819",Other,,
1612,982719,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S020819",Other,,
1613,982720,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020819",Other,,
1614,982721,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S020819,Other,,
1615,982722,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020819",Other,,
1616,982723,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020819",Other,,
1617,982724,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020819",Other,,
1618,982725,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020819",Other,,
1619,982726,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020819",Other,,
1620,982727,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020819",Other,,
1621,982728,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020819",Other,,
1622,982729,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S020819",Other,,
1623,982730,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S020819",Other,,
1624,982731,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020819",Other,,
1625,982732,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S020819",Other,,
1626,982733,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S020819",Other,,
1627,982734,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S020819",Other,,
1628,982735,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S020819",Other,,
1629,982736,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020819,Other,,
1630,982737,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020819",Other,,
1631,982738,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020819,Other,,
1632,982739,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020819",Other,,
1633,982740,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020819",Other,,
1634,982741,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020819",Other,,
1635,982742,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020819",Other,,
1636,982743,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020819",Other,,
1637,982744,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020819",Other,,
1638,982745,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020819",Other,,
1639,982746,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020819",Other,,
1640,982747,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020819",Other,,
1641,982748,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S020819",Other,,
1642,982749,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S020819",Other,,
1643,982750,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S020819,Other,,
1644,982751,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S020819",Other,,
1645,982752,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020819",Other,,
1646,982753,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020819",Other,,
1647,984742,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020819",Other,,
1648,984743,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020819",Other,,
1649,984744,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020819",Other,,
1650,984745,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020819",Other,,
1651,984746,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020819",Other,,
1652,984747,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020819",Other,,
1653,984748,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020819",Other,,
1654,984749,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020819",Other,,
1655,984750,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020819",Other,,
1656,984751,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020819",Other,,
1657,984752,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S020819",Other,,
1658,984753,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S020819",Other,,
1659,984754,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S020819",Other,,
1660,984755,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S020819",Other,,
1661,984756,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S020819",Other,,
1662,984757,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S020819",Other,,
1663,984758,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S020819",Other,,
1664,984759,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020819,Other,,
1665,984760,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020819,Other,,
1666,984761,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020819",Other,,
1667,984762,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020819",Other,,
1668,984763,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020819",Other,,
1669,984764,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020819",Other,,
1670,984765,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S020819",Other,,
1671,984766,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S020819",Other,,
1672,984767,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020819",Other,,
1673,984768,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S020819",Other,,
1674,984769,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S020819",Other,,
1675,984770,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S020819",Other,,
1676,984771,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S020819",Other,,
1677,984772,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S020819",Other,,
1678,984773,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020819",Other,,
1679,984774,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S020819",Other,,
1680,984775,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S020819",Other,,
1681,984776,1,3,,103167833,4212,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020819,Other,,
1682,984777,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S020819",Other,,
1683,985246,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020819",Other,,
1684,985247,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020819",Other,,
1685,985248,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020819",Other,,
1686,985249,1,3,,103167833,4212,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020819",Other,,
1687,1053131,3,1,,92763439,4212,Active,2853980.0,,,,Counterscreen for inhibitors of LEDGF/p75-dependent integration: TR-FRET-based biochemical high throughput counterscreen assay to identify activators of HIV-1 Integrase multimerization,Screening,,
1688,1053131,3,1,,92763439,4212,Active,6708281.0,11168.0,,,Counterscreen for inhibitors of LEDGF/p75-dependent integration: TR-FRET-based biochemical high throughput counterscreen assay to identify activators of HIV-1 Integrase multimerization,Screening,,
1689,1053135,2,1,,92763439,4212,Inactive,,,,,Counterscreen for inhibitors of LEDGF/p75-dependent integration: TR-FRET-based biochemical high throughput counterscreen assay to identify inhibitors that optically interfere with TR-FRET measurement,Screening,,
1690,1053136,1,1,,92763439,4212,Active,2853980.0,,,,Confirmation assay for inhibitors of LEDGF/p75-dependent integration: TR-FRET-based biochemical high throughput assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1691,1053136,1,1,,92763439,4212,Active,6708281.0,11168.0,,,Confirmation assay for inhibitors of LEDGF/p75-dependent integration: TR-FRET-based biochemical high throughput assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1692,1053173,1,1,,92763439,4212,Active,109633019.0,7468.0,2.34,AC50_uM,"Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_Dose_CherryPick_Activity",Confirmatory,,
1693,1053174,1,1,,92763439,4212,Active,,,2.03,AbsAC35_uM,ALPHAscreen artifact counterscreen Measured in Biochemical System Using Plate Reader - 7053-03_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1694,1053197,1,1,,92763439,4212,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
1695,1053260,1,4,,103167833,4212,Unspecified,118206.0,1813.0,,,Antagonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin assessed as inhibition of agonist-induced effect at 50 uM after 15 mins by luminometric analysis relative to haloperidol,Other,24088053.0,
1696,1053262,1,4,,103167833,4212,Unspecified,118206.0,1813.0,,,Agonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin at 100 uM by luminometric analysis relative to quinpirol,Other,24088053.0,
1697,1053264,1,4,,103167833,4212,Unspecified,118228.0,1812.0,,,Antagonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as inhibition of agonist-induced cAMP accumulation at 100 uM preincubated for 10 mins prior to agonist addition measured after 30 mins by HTRF assay relative to SCH23390,Other,24088053.0,
1698,1053266,1,4,,103167833,4212,Unspecified,118228.0,1812.0,,,Agonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as stimulation of cAMP accumulation at 100 uM after 30 mins by HTRF assay relative to SKF81297,Other,24088053.0,
1699,1070859,1,4,,103167833,4212,Unspecified,6226780.0,7015.0,,,Inhibition of human tert transcriptional activity assessed as SEAP activity at 100 uM after 24 hrs by SEAP reporter assay,Other,24051300.0,
1700,1070860,1,4,,103167833,4212,Unspecified,6226780.0,7015.0,,,Inhibition of human tert transcriptional activity assessed as SEAP activity at 10 uM after 24 hrs by SEAP reporter assay,Other,24051300.0,
1701,1070861,1,4,,103167833,4212,Unspecified,6226780.0,7015.0,,,Inhibition of human tert transcriptional activity assessed as SEAP activity at 1 uM after 24 hrs by SEAP reporter assay,Other,24051300.0,
1702,1070862,1,1,,103167833,4212,Unspecified,,,,,Cytotoxicity against human H1299 cells assessed as cell viability at 100 uM after 48 hrs by MTT assay,Other,24051300.0,
1703,1070863,1,1,,103167833,4212,Unspecified,,,,,Cytotoxicity against human H1299 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay,Other,24051300.0,
1704,1070864,1,1,,103167833,4212,Unspecified,,,,,Cytotoxicity against human H1299 cells assessed as cell viability at 1 uM after 48 hrs by MTT assay,Other,24051300.0,
1705,1079931,1,1,,103167833,4212,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
1706,1079932,1,1,,103167833,4212,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
1707,1079933,1,1,,103167833,4212,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
1708,1079934,1,1,,103167833,4212,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
1709,1079935,1,1,,103167833,4212,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
1710,1079936,1,1,,103167833,4212,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
1711,1079937,1,1,,103167833,4212,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
1712,1079938,1,1,,103167833,4212,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
1713,1079939,1,1,,103167833,4212,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
1714,1079940,1,1,,103167833,4212,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
1715,1079941,1,1,,103167833,4212,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
1716,1079942,1,1,,103167833,4212,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
1717,1079943,1,1,,103167833,4212,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
1718,1079944,1,1,,103167833,4212,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
1719,1079945,1,1,,103167833,4212,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
1720,1079946,1,1,,103167833,4212,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
1721,1079947,1,1,,103167833,4212,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
1722,1079948,1,1,,103167833,4212,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
1723,1079949,1,1,,103167833,4212,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
1724,1114986,1,2,,103167833,4212,Unspecified,,,,,Inhibition of nuclear DNA synthesis in Rattus norvegicus (rat) C6 cells assessed as decrease in bromodeoxyuridine incorpoRattus norvegicus (rat)ion measured during S phase at IC50 after 24 hr by ELISA,Other,,
1725,1114988,1,2,,103167833,4212,Unspecified,,,,,Inhibition of nuclear DNA synthesis in Homo sapiens (human) A549 cells assessed as decrease in bromodeoxyuridine incorporation measured during S phase at IC50 after 24 hr by ELISA,Other,,
1726,1114999,1,2,,103167833,4212,Unspecified,,,,,Inhibition of nuclear DNA synthesis in Rattus norvegicus (rat) C6 cells assessed as decrease in bromodeoxyuridine incorpoRattus norvegicus (rat)ion measured during S phase after 24 hr by ELISA,Other,,
1727,1115000,1,2,,103167833,4212,Unspecified,,,,,Inhibition of nuclear DNA synthesis in Homo sapiens (human) A549 cells assessed as decrease in bromodeoxyuridine incorporation measured during S phase after 24 hr by ELISA,Other,,
1728,1115003,1,2,,103167833,4212,Inconclusive,,,,,Cytotoxicity against Mus musculus (mouse) NIH/3T3 cells after 24 hr by MTT assay,Other,,
1729,1115004,1,2,,103167833,4212,Unspecified,,,,,Cytotoxicity against Rattus norvegicus (rat) C6 cells after 24 hr by MTT assay,Other,,
1730,1115005,1,2,,103167833,4212,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) A549 cells after 24 hr by MTT assay,Other,,
1731,1117319,1,2,,92763439,4212,Inconclusive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
1732,1117319,1,2,,92763439,4212,Inconclusive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
1733,1129361,1,1,,103167833,4212,Unspecified,,,,,Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis,Other,24601604.0,
1734,1129639,1,1,,103167833,4212,Active,,,0.0266,IC50,Cytotoxicity against HEK293 cells overexpressing ABCG2 after 72 hrs by MTT assay,Confirmatory,24611893.0,
1735,1129642,1,1,,103167833,4212,Active,,,0.01,IC50,Cytotoxicity against HEK293 cells after 72 hrs by MTT assay,Confirmatory,24611893.0,
1736,1130148,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse B16 cells allografted in BDF1 mouse assessed as survival at 2 mg/kg qd for 9 days,Other,458801.0,
1737,1130149,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse B16 cells allografted in BDF1 mouse at 2 mg/kg qd for 9 days relative to control,Other,458801.0,
1738,1130150,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse B16 cells allografted in BDF1 mouse assessed as survival at 1 mg/kg qd for 9 days,Other,458801.0,
1739,1130151,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse B16 cells allografted in BDF1 mouse at 1 mg/kg qd for 9 days relative to control,Other,458801.0,
1740,1130152,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse B16 cells allografted in BDF1 mouse assessed as survival at 0.5 mg/kg qd for 9 days,Other,458801.0,
1741,1130153,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse B16 cells allografted in BDF1 mouse at 0.5 mg/kg qd for 9 days relative to control,Other,458801.0,
1742,1130154,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse B16 cells allografted in BDF1 mouse assessed as survival at 0.25 mg/kg qd for 9 days,Other,458801.0,
1743,1130155,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse B16 cells allografted in BDF1 mouse at 0.25 mg/kg qd for 9 days relative to control,Other,458801.0,
1744,1130156,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse Colon 26 cells allografted in CDF1 mouse assessed as survival at 1.08 mg/kg qd for 9 days,Other,458801.0,
1745,1130157,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse Colon 26 cells allografted in CDF1 mouse at 1.08 mg/kg qd for 9 days relative to control,Other,458801.0,
1746,1130158,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse Colon 26 cells allografted in CDF1 mouse assessed as survival at 0.69 mg/kg qd for 9 days,Other,458801.0,
1747,1130159,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse Colon 26 cells allografted in CDF1 mouse at 0.69 mg/kg qd for 9 days relative to control,Other,458801.0,
1748,1130160,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse Colon 26 cells allografted in CDF1 mouse assessed as survival at 0.39 mg/kg qd for 9 days,Other,458801.0,
1749,1130161,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse Colon 26 cells allografted in CDF1 mouse at 0.39 mg/kg qd for 9 days relative to control,Other,458801.0,
1750,1130162,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse assessed as survival at 18 mg/kg qd for 9 days,Other,458801.0,
1751,1130163,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse at 18 mg/kg qd for 9 days relative to control,Other,458801.0,
1752,1130164,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse assessed as survival at 10.8 mg/kg qd for 9 days,Other,458801.0,
1753,1130165,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse at 10.8 mg/kg qd for 9 days relative to control,Other,458801.0,
1754,1130166,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse assessed as survival at 4 mg/kg qd for 9 days,Other,458801.0,
1755,1130167,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse at 4 mg/kg qd for 9 days relative to control,Other,458801.0,
1756,1130168,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse assessed as survival at 2 mg/kg qd for 9 days,Other,458801.0,
1757,1130169,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse at 2 mg/kg qd for 9 days relative to control,Other,458801.0,
1758,1130170,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse assessed as survival at 1 mg/kg qd for 9 days,Other,458801.0,
1759,1130171,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse at 1 mg/kg qd for 9 days relative to control,Other,458801.0,
1760,1130172,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 2 mg/kg qd for 9 days,Other,458801.0,
1761,1130173,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse at 2 mg/kg qd for 9 days relative to control,Other,458801.0,
1762,1130174,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 1 mg/kg qd for 9 days,Other,458801.0,
1763,1130175,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse at 1 mg/kg qd for 9 days relative to control,Other,458801.0,
1764,1130176,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 0.5 mg/kg qd for 9 days,Other,458801.0,
1765,1130177,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse at 0.5 mg/kg qd for 9 days relative to control,Other,458801.0,
1766,1130178,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 0.25 mg/kg qd for 9 days,Other,458801.0,
1767,1130179,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse at 0.25 mg/kg qd for 9 days relative to control,Other,458801.0,
1768,1130180,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 0.12 mg/kg qd for 9 days,Other,458801.0,
1769,1130181,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse at 0.12 mg/kg qd for 9 days relative to control,Other,458801.0,
1770,1130182,1,1,,103167833,4212,Active,,,,,Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 0.06 mg/kg qd for 9 days,Other,458801.0,
1771,1130183,1,1,,103167833,4212,Unspecified,,,,,Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse at 0.06 mg/kg qd for 9 days relative to control,Other,458801.0,
1772,1130617,1,1,,103167833,4212,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase of median life span at 6.2 mg/kg, ip on day 1, 5 and 9 measured up to 60 days relative to control",Other,490545.0,
1773,1130623,1,1,,103167833,4212,Unspecified,,,,,"Antitumor activity against mouse B16 cells allografted in BDF1 mouse assessed as increase of median life span at 3.1 mg/kg, ip on day 1 to 9 measured up to 80 days relative to control",Other,490545.0,
1774,1132468,1,1,,103167833,4212,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as increase in survival time at 2 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1775,1132469,1,1,,103167833,4212,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as increase in survival time at 1 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1776,1132470,1,1,,103167833,4212,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as increase in survival time at 0.5 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1777,1132471,1,1,,103167833,4212,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as increase in survival time at 0.25 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1778,1132472,1,1,,103167833,4212,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as increase in survival time at 0.12 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1779,1132473,1,1,,103167833,4212,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as increase in survival time at 0.06 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1780,1132488,1,1,,103167833,4212,Active,,,,,Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as mouse survival at 2 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1781,1132489,1,1,,103167833,4212,Active,,,,,Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as mouse survival at 0.5 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1782,1132490,1,1,,103167833,4212,Active,,,,,Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as mouse survival at 0.25 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1783,1132491,1,1,,103167833,4212,Active,,,,,Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as mouse survival at 0.12 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1784,1132492,1,1,,103167833,4212,Active,,,,,Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as mouse survival at 0.06 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1785,1132507,1,1,,103167833,4212,Unspecified,,,,,Toxicity in mouse P388 cells allografted BDF1 mouse assessed as body weight difference at 2 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1786,1132508,1,1,,103167833,4212,Unspecified,,,,,Toxicity in mouse P388 cells allografted BDF1 mouse assessed as body weight difference at 1 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1787,1132509,1,1,,103167833,4212,Unspecified,,,,,Toxicity in mouse P388 cells allografted BDF1 mouse assessed as body weight difference at 0.5 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1788,1132510,1,1,,103167833,4212,Unspecified,,,,,Toxicity in mouse P388 cells allografted BDF1 mouse assessed as body weight difference at 0.25 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1789,1132511,1,1,,103167833,4212,Unspecified,,,,,Toxicity in mouse P388 cells allografted BDF1 mouse assessed as body weight difference at 0.12 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1790,1132512,1,1,,103167833,4212,Unspecified,,,,,Toxicity in mouse P388 cells allografted BDF1 mouse assessed as body weight difference at 0.06 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1791,1132519,1,1,,103167833,4212,Unspecified,,,,,Antitumor activity against mouse B16 cells allografted in BDF1 mouse assessed as increase in survival time at 1 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1792,1132520,1,1,,103167833,4212,Unspecified,,,,,Antitumor activity against mouse B16 cells allografted in BDF1 mouse assessed as increase in survival time at 0.5 mg/kg administered 24 hrs post challenge relative to control,Other,628005.0,
1793,1152333,1,1,,103167833,4212,Active,,,11.05,IC50,Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,24794747.0,
1794,1159524,1,1,,92763439,4212,Inconclusive,,,17.7828,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1795,1159580,2,1,,268734945,4212,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1796,1159580,2,1,,273002885,4212,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1797,1159606,1,1,,92763439,4212,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
1798,1159607,2,1,,312309827,4212,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1799,1167196,1,1,,103167833,4212,Active,,,,,Intrinsic cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay,Other,25272055.0,
1800,1197743,1,2,,103167833,4212,Unspecified,12643959.0,10599.0,,,Inhibition of human OATP1B1-mediated [3H]estrone 3-sulfate at 100 uM after 5 mins relative to control,Other,25618019.0,
1801,1197745,1,2,,103167833,4212,Unspecified,27734563.0,28234.0,,,Inhibition of human OATP1B3-mediated [3H]CCK-8 at 100 uM after 5 mins relative to control,Other,25618019.0,
1802,1197747,1,2,,103167833,4212,Active,27734563.0,28234.0,,IC50,Inhibition of human OATP1B3-mediated [3H]CCK-8 after 5 mins by Dixon plot method,Confirmatory,25618019.0,
1803,1207752,1,1,,103167833,4212,Active,,,22.5,IC50,"Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits",Confirmatory,23812503.0,
1804,1209581,1,2,,103167833,4212,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis,Other,21149540.0,
1805,1209582,1,1,,103167833,4212,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs,Other,21149540.0,
1806,1209583,1,1,,103167833,4212,Unspecified,,,,,"Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma",Other,21149540.0,
1807,1209589,1,1,,103167833,4212,Active,,,,,Drug uptake in Sprague-Dawley rat brain slices at 100 nM after 5 hrs in presence of 10 uM of fumitremorgin-C,Other,21149540.0,
1808,1209590,1,1,,103167833,4212,Active,,,,,Drug uptake in Sprague-Dawley rat brain slices at 100 nM after 5 hrs in presence of 20 uM of MK-571,Other,21149540.0,
1809,1209591,1,1,,103167833,4212,Active,,,,,Drug uptake in Sprague-Dawley rat brain slices at 100 nM after 5 hrs in presence of 10 uM of fumitremorgin-C and 20 uM of MK-571,Other,21149540.0,
1810,1209592,1,1,,103167833,4212,Unspecified,,,,,"Dissociation constant, pKa of the basic compound by capillary electrophoresis-mass spectrometry analysis",Other,21149540.0,
1811,1209593,1,1,,103167833,4212,Unspecified,,,,,"Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis",Other,21149540.0,
1812,1221956,1,1,,103167833,4212,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
1813,1221957,1,1,,103167833,4212,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
1814,1221958,1,1,,103167833,4212,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
1815,1221960,1,1,,103167833,4212,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
1816,1221961,1,1,,103167833,4212,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
1817,1221962,1,1,,103167833,4212,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
1818,1221963,1,1,,103167833,4212,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
1819,1221964,1,1,,103167833,4212,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
1820,1221965,1,1,,103167833,4212,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
1821,1221982,1,1,,103167833,4212,Unspecified,,,,,Fraction absorbed in human,Other,21051535.0,
1822,1224824,1,1,,162108252,4212,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
1823,1224825,1,1,,162108252,4212,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
1824,1224857,2,1,,162108252,4212,Inactive,,,0.2348,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1825,1224859,2,1,,90341083,4212,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1826,1224859,2,1,,162108252,4212,Inconclusive,,,23.485,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1827,1224863,1,1,,176484413,4212,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1828,1224863,1,1,,176484851,4212,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1829,1224863,1,1,,316919144,4212,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1830,1224865,1,2,,92763439,4212,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
1831,1224905,2,1,,92309061,4212,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1832,1224905,2,1,,92309061,4212,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1833,1233368,1,1,,103167833,4212,Active,,,0.025,IC50,Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,25998504.0,
1834,1233369,1,1,,103167833,4212,Active,,,0.044000000000000004,IC50,Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay,Confirmatory,25998504.0,
1835,1233370,1,1,,103167833,4212,Active,,,0.013000000000000001,IC50,Antiproliferative activity against human FM3 cells after 72 hrs by MTT assay,Confirmatory,25998504.0,
1836,1233371,1,1,,103167833,4212,Active,,,0.01,IC50,Antiproliferative activity against human Ishikawa cells after 72 hrs by MTT assay,Confirmatory,25998504.0,
1837,1233372,1,1,,103167833,4212,Active,,,0.005,IC50,Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay,Confirmatory,25998504.0,
1838,1233373,1,1,,103167833,4212,Active,,,0.006,IC50,Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay,Confirmatory,25998504.0,
1839,1233374,1,1,,103167833,4212,Active,,,0.073,IC50,Antiproliferative activity against human MES-SA/Dx5 cells after 72 hrs by MTT assay,Confirmatory,25998504.0,
1840,1233375,1,1,,103167833,4212,Unspecified,,,,,Ratio of IC50 for human MES-SA/Dx5 cells to IC50 for human MES-SA cells,Other,25998504.0,
1841,1236570,1,1,,103167833,4212,Active,,,0.026000000000000002,IC50,Cytotoxicity against human MCF7 cells,Confirmatory,25811651.0,
1842,1236574,1,1,,103167833,4212,Active,,,0.435,IC50,Cytotoxicity against human MCF-7 FLV1000 cells expressing ABCB2,Confirmatory,25811651.0,
1843,1259229,1,1,,103167833,4212,Unspecified,,,,,Percentage of administered dose recovered as unchanged drug in urine within 48 h of drug administration,Other,,
1844,1259252,1,1,,162108252,4212,Active,169655958.0,,0.1663,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
1845,1259253,1,1,,162108252,4212,Active,169655958.0,,0.0935,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
1846,1259255,1,1,,162108252,4212,Active,169655958.0,,0.059000000000000004,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
1847,1259256,1,1,,162108252,4212,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
1848,1259313,1,1,,92763439,4212,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
1849,1259318,1,1,,92763439,4212,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
1850,1259325,1,2,,336954446,4212,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
1851,1259400,1,1,,92763439,4212,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
1852,1259407,1,1,,363905554,4212,Inactive,,,,,CCRIS mutagenicity studies,Other,,
1853,1259408,1,1,,363897753,4212,Active,,,,,GENE-TOX mutagenicity studies,Other,,
1854,1259415,1,1,,92763439,4212,Active,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
1855,1259416,1,2,,340080269,4212,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1856,1259416,1,2,,375174706,4212,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1857,1259418,1,1,,89449175,4212,Active,56786138.0,3458.0,0.128,AC50_uM,Toxoplasma gondii at dose in the presence of IFN-y,Confirmatory,,
1858,1259420,1,1,,89449175,4212,Active,56786138.0,3458.0,0.209,AC50_uM,Toxoplasma gondii at dose in the absence of IFN-y,Confirmatory,,
1859,1259421,1,1,,340080269,4212,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1860,1259421,1,1,,375174706,4212,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1861,1259423,1,2,,354748545,4212,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1862,1259423,1,2,,354909931,4212,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1863,1259423,1,2,,354909946,4212,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1864,1259423,1,2,,354909999,4212,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
